Top

Naveen Pemmaraju, M.D.

Department of Leukemia, Division of Cancer Medicine

About Dr. Naveen Pemmaraju

After completing my Internal Medicine training at Johns Hopkins in the Osler Medical Program (2005-2008), I subsequently completed Hematology/Oncology training at MD Anderson Cancer Center Fellowship Program (MDACC; 2008-2011). I was selected as a Chief Fellow in my second year of fellowship training. I obtained ABIM board certification in Internal Medicine, Hematology and Oncology, and continued my career at MDACC as an Assistant Professor in the Department of Leukemia (start date 07/2011). In September 2017, I was promoted to Associate Professor in the Department of Leukemia. I maintain an active clinical schedule, during which I see patients 2-full days per week; including 2-months of inpatient service per year. I have fellow teaching responsibilities as the Leukemia Hematology/Oncology Course Director and was the sole recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. I was recognized as our institution’s Faculty Educator of the Quarter in December 2022.

My clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Myeloproliferative Neoplasms (MPN) and Acute Myeloid Leukemia (AML). I have authored/co-authored over 265 publications in the medical literature (all available in PubMed). I have presented our group's work, as first author, in oral presentations at numerous national/international meetings: ASCO, ASH, EHA, AACR. Under the direct mentorship of Dr. Hagop Kantarjian, and Dr. Marina Konopleva, I have established our group's first, active, BPDCN clinic; which now serves as a worldwide referral base and has brought in many new patients to MDACC. This clinic continues to expand as one of the world’s most active BPDCN research programs with dedicated infrastructure and ample support for clinical and translational studies. For these efforts, I have been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020. I am the PI/co-PI of many active clinical trials in the Leukemia department, for a translational sample study of patients with BPDCN, and was awarded a grant for identifying prognostic biomarkers in patients with BPDCN. I have developed key collaborative projects and lead groups in the areas BPDCN, MPN and AML, with clinical, hematopathology and dermatopathology teams; both internally and externally. I serve as our department’s Executive Director for the MDACC Network, helping to improve and expand upon leukemia and malignant hematology collaborations and clinical trials networking, and am an active member of the ASH Communications Committee, currently serving a 4-year term.

Meet Naveen Pemmaraju, M.D.

In the News

Illustration of magnifying glass focused on a DNA strand

Leukemia specialists: How advances in measurable residual disease (MRD) are improving cancer care

ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis

Medical illustration of healthy red platelets and cancerous white blood cells drifting along inside a pink-walled capillary

Understanding the types of leukemia

Reflections on caring for cancer patients during the COVID-19 pandemic

New blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment improves outlook for many patients

Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies

Cancerwise blog post: Naveen Pemmaraju, M.D., discusses acute myeloid leukemia (AML)

Acute myeloid leukemia: What to know

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

· Patients with AML and BPDCN: CD123-targeted clinical trial with SL-401. MDACC PI: Marina Konopleva, Co-PI: Naveen Pemmaraju. In this clinical trial, we and others have identified a marker present on many AML blasts, called CD123 (or IL3R alpha). Patients are offered this novel therapy with either AML, or for patients with BPDCN, a tumor in which almost all patients express high levels of CD123. This trial is open and currently enrolling patients. https://clinicaltrials.gov/ct2/show/NCT02113982

· Patients with Myelofibrosis(MF): Treatment with a Smac Mimetic, LCL-161. PI: Naveen Pemmaraju. Co-PI: Srdan Verstovsek. This is a single-institutional , Investigator-initiated phase II clinical trial. In this study, we are treating patients with a new type of targeted therapy that aims to promote cell death (apoptosis) in cancer cells, which have been found in many cases to overexpress certain proteins that prevent them from dying normally. I will be collaborating with a senior scientist in our group (Dr Bing Carter) to test all patient samples for correlative studies of the markers of cell death, to help us understand the exact nature of the drug targeting the tumor cells. This trial is currently enrolling patients. https://clinicaltrials.gov/ct2/show/NCT02098161

· Patients with Advanced Myeloproliferative Neoplams (MPNs): CMML, HES, SM, MF. Treatment with Targeted Therapy with SL-401. PI: Naveen Pemmaraju, Co-PI: Srdan Verstovsek. https://clinicaltrials.gov/ct2/show/NCT02268253

Education & Training

Degree-Granting Education

2005	University of Arkansas for Medical Sciences, Little Rock, Arkansas, US, MD
2001	Tulane University, New Orleans, Louisiana, US, Cell and Molecular Biology, BS

Postgraduate Training

2008-2011	Clinical Fellowship, Hematology and Medical Oncology, MD Anderson Cancer Center, Houston, Texas
2005-2008	Clinical Residency, Internal Medicine, Johns Hopkins Hospital, Osler Internal Medicine Program, Baltimore, Maryland

Licenses & Certifications

2012	Hematology
2011	Medical Oncology
2008	Texas State Medical License
2008	American Board of Internal Medicine

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017

Administrative Appointments/Responsibilities

Executive Director, Cancer Network, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present

Director, Cancer Network, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present

Director, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

Hematology Consultant, Cancer Network, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2022

Course Director, Leukemia Rotation, Hematology/Oncology Fellowship Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present

Co-Chair, Leukemia Hematology Grand Rounds, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2021

Other Professional Positions

Member, Patient Power Advisory Panel, USA, 2021 - 2021

Chief Fellow Housestaff Education, Hematology/Oncology, The University of Texas MD Anderson Cancer Center Fellowship Program, Houston, TX, 2009 - 2010

Extramural Institutional Committee Activities

Co-Chair, Scientific Review Committee (SRC) #3, The University of Texas MD Anderson Cancer Center, 2021 - Present

Vice Chair, Pharmacy and Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, Clinical Research Committee (CRC), The University of Texas MD Anderson Cancer Center, 2015 - 2021

Member, Pharmacy and Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2021

Member, Transfusion Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2016

Member, Clinical Competence Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, Fellowship Steering Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present

Member, OncoLog Editorial Board, The University of Texas MD Anderson Cancer Center, 2012 - 2017

Member, Interviewing Committee, MD Anderson Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, 2010 - Present

Editorial Activities

Contributing Editor, The Hematologist, 2026 - 2028

Associate Editor, Blood Cancers Today, 2022 - 2023

Editorial Board Member, Journal of Immunotherapy and Precision Oncology (JIPO), 2020 - Present

Editorial Board Chair, HemOnc Times, 2018 - 2019

Advisory Board, Oncology Times, 2016 - 2019

Staff Writer, ASH Daily News, 2016

Section Editor, Elsevier, 2016 - Present

Honors & Awards

2024	International Academy for Clinical Science 2024 Special Achievement Award, CME-Congress
2023 - 2024	Inducted Member, Academy of Health Science Education (AHSE), The University of Texas MD Anderson Cancer Center
2023	Faculty Educator of the Year, The University of TX MD Anderson Cancer Center
2023 - 2024	Honorable Distinction, SOHO
2022 - 2023	2022 MPN Hero Award, CURE, 10th Annual MPN Heroes Program
2022 - 2023	Faculty Educator of the Fourth Quarter, The University of Texas MD Anderson Cancer Center, Faculty Educator Awards Committee
2021 - 2022	Top 1% Clinical Provider Teams, The University of Texas MD Anderson Cancer Center, Physicians Referral Service and Patient Experience
2020	2020 Quantum Leap Award for Improving Young Adult Patient Care, Dan’s House of Hope (DHOH)
2020	Gerald P. Bodey Award for Excellence in Education, The University of TX MD Anderson Cancer Center
2018 - 2019	Top 10% for Exceptional Communication with Patients and Families, The University of TX MD Anderson Cancer Center
2013 - 2024	ACP Fellowship, FACP, American College of Physicians
2013 - 2014	ASH CRTI Program, American Society of Hematology
2012	M. D. Anderson Apple Award for Excellence in Patient Education, The University of TX MD Anderson Cancer Center
2011 - 2024	Advocacy Leadership Institute, American Society of Hematology
2011	Merit Award, American Society of Clinical Oncology
2010 - 2011	The Kimberly Patterson Fellowship in Leukemia Research, The University of TX MD Anderson Cancer Center
2010	Celgene 2010 Future Leaders Award for Clinical Research in Hematology, Celgene
2010	Jesse H. Jones Outstanding Teaching Fellow Award, The University of TX MD Anderson Cancer Center
2005	Elected, Class President and Student Commencement Speaker, University of Arkansas for Medical Sciences
2005	H. Elvin Shuffield, MD Outstanding Medical Leadership Award, University of Arkansas for Medical Sciences
2004 - 2005	Academic Scholarship, Arkansas Blood and Cancer Society
2004 - 2005	Academic Scholarship, Arkansas Medical Society Alliance AMA Foundation
2004 - 2005	Outstanding Geriatrics Medical Student, Junior Clerkship Award
2003 - 2004	George Link Ackerman Academic Medical Scholarship, University of Arkansas for Medical Sciences
2002 - 2003	Academic Medical Scholarship, Inaugural Class of 1957 UAMS Alumni
2000	Outstanding Peer Health Advocate of the Year, Student Crest Leadership Award

Professional Memberships

Clinical Lymphoma, Myeloma & Leukemia Editorial Board

2020 - Present

Journal of Immunotherapy and Precision Oncology (JIPO) Editorial Board

2020 - 2022

American Soceity of Clinical Oncology (ASCO) Cancer.Net Editorial Board

2020 - 2021

The American Society of Hematology (ASH) Committee on Communications

2020 - 2023

SWOG

2015 - Present

Texas Medical Association

2013 - Present

Harris County Medical Society

2013 - Present

American Association for the Advancement of Science

2012 - Present

International CML Foundation

2012 - Present

School of Science and Engineering Tulane Health Leaders Alumni Group (THLAG)

2012 - Present

Johns Hopkins Medical and Surgical Association

2012 - Present

American College of Physicians

2011 - Present

American Society for Bone and Mineral Research

2011 - 2015

American Association for Cancer Research

2010 - Present

American Society of Clinical Oncology (ASCO)

2009 - Present

American Society of Hematology (ASH)

2008 - Present

Selected Presentations & Talks

Local Presentations

2023. Lessons Learned in Studying Ultra-Rare Hematologic Malignancies: Focus on Targeting CD123 in BPDCN. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2022. co-chair, Physician Engagement Breakout Session. Conference. MD Anderson Cancer Network. Houston, TX, US.
2022. Oral Abstract | MPN-469 | Rusfertide (Ptg-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera. Conference. Society of Hematology Oncology (SOHO). Houston, TX, US.
2022. Novel Agents and Evolving Strategies in Myeloproliferative Neoplasms. Conference. Medical Learning Institute. Houston, TX, US.
2021. Hematologic Malignancies: Pearls for the Hospitalist. Conference. The University of TX MD Anderson Cancer Center. Houston, TX, US.
2019. MD Anderson Multidisciplinary Care Discussion Panel. Conference. MD Anderson Cancer Network. Houston, TX, US.
2010. Outcomes with FLT3 inhibitors: Personalized Targeted Therapy for Acute Myeloid Leukemia. Conference. MD Anderson Cancer Center. Houston, TX, US.

Regional Presentations

2023. Evolving Targets for MPN Therapy. Conference. MPN Education Foundation. Phoenix, AZ, US.
2023. A Patient Education Webinar: Live Q/A in Real Time with a Physician. Conference. MPN Advocacy and Education International. Virtual, US.
2022. Novel Agents and Evolving Strategies in Myeloproliferative Neoplasms. Conference. 2022 Society of Hematologic Oncology (SOHO). Virtual, US.
2022. Novel Targeted Therapies for Myelofibrosis: Targeting BCLxL in MPNs. Conference. UT Health San Antonio, MD Anderson Cancer Center. San Antonio, TX, US.
2022. Opinions in the Myelofibrosis: An Interactive Local Virtual Workshop. Conference. Curio Science. Virtual, New Orleans, US.
2022. JAK Inhibitors for the Treatment of Cytopenic Myelofibrosis. Conference. Curio Science. Virtual, Kansas, Nebraska, Oklahoma, US.
2022. Current Management and Emerging Challenges in MF. Conference. Illinois Cancer Specialists. Virtual, IL, US.
2022. Current Management and Emerging Challenges in MF. Conference. Cancer Center of Kansas. Virtual, KS, US.
2022. JAK Inhibitors for the Treatment of Cytopenic Myelofibrosis. Conference. Curio Science. Virtual, MO, US.
2022. Evolving Treatment Landscape for Cytopenic Myelofibrosis. Conference. Curio Science. Virtual, TN, US.
2021. Evolving Treatment Landscape for Cytopenic Myelofibrosis. Conference. Curio Science. Virtual, US.
2021. Myelofibrosis: Mechanism of Disease. Conference. Triptych Health Partners. Virtual, US.
2021. Panelist: Twitter. Conference. The University of TX MD Anderson Cancer Center. Virtual, TX, US.
2021. Cancer Care – Will cancer care look & feel the same way it looked pre-covid-19?. Conference. Leukemia & Lymphoma Society (LLS). Virtual, US.
2021. Panelist: Updates in AYA Tumor Management. Conference. The University of TX MD Anderson Cancer Center. Virtual, TX, US.
2020. Case Studies in Blastic Plasmacytoid Dendritic Cell Neoplasm: Tackling the Diagnostic Challenge. Conference. MedscapeLIVE!. Virtual, US.
2020. Novel Targeted Therapies Beyond JAKi's. Conference. UT Health San Antonio, MD Anderson Cancer Center. Virtual, TX, US.
2020. Keynote Speaker: Current Topics in MPNs. Conference. Incyte. Virtual, US.
2019. Experience with Current Management and Treatment of Patients with Myelofibrosis. Conference. AbbVie. New York, NY, US.

National Presentations

2023. High Risk Myelofibrosis. Invited. Targeted Oncology. Houston, TX, US.
2023. Current management paradigm in MF: Standard of Care. Invited. APTITUDE Health, US.
2023. Risk Stratifying Patients With ET. Invited. MJH Life Sciences. Virtual, US.
2023. BPDCN Case Presentation. Invited. APTITUDE Health, Targeted Oncology. Virtual, TX, US.
2023. Myeloproliferative Neoplasms Including Chronic Myeloid Leukemia. Invited. American Society of Hematology (ASH). San Francisco, CA, US.
2022. Tagraxofusp, a CD123-directed Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial. Conference. American Society of Hematology (ASH). New Orleans, LA, US.
2022. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort. Conference. American Society of Hematology (ASH). New Orleans, LA, US.
2022. Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera. Invited. American Society of Hematology (ASH). New Orleans, LA, US.
2022. A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage. Conference. American Society of Hematology (ASH). New Orleans, LA, US.
2022. Identifying and Managing Patients with BPDCN: Practical Insights from the Multidisciplinary Team. Invited. Medscape, Menarini. New Orleans, LA, US.
2022. Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy. Invited. Physicians Education Resource, LLC. New Orleans, LA, US.
2022. Beware of toxicities, complications to monitor for as we enter combination era. Invited. MJH Life Sciences. Virtual.
2022. How to build and maintain a rare disease clinical and research program. Invited. 1st Congress on Myeloproliferative Neoplasms Controversies and Debates (MPNCo&D). Virtual.
2022. Anemia in MF: emerging area for novel approaches. Invited. GSK. Virtual.
2022. Debate: Novel therapies in combinations in MF: an emerging new era: With JAKi – important steps forward in patient management. Invited. 1st Congress on Myeloproliferative Neoplasms Controversies and Debates (MPNCo&D). Virtual.
2022. Updates in the Management of Polycythemia Vera (PV). Invited. Bio Ascend. Virtual, US.
2022. Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy. Invited. American Association for Cancer Reserach (AACR). New Orleans, LA, US.
2022. Approach to Diagnosis and Treatment of BPDCN. Invited. Great Debates & Updates in Hematologic Malignancies. Virtual, US.
2022. Navitoclax and Bcl-xL in Myelofibrosis. Invited. DAVA Oncology. Amelia Island, FL, US.
2022. Management of Myelofibrosis in the 2020s: Exciting Targets on the Horizon. Invited. DAVA Oncology. Amelia Island, FL, US.
2022. Moderator: Perspectives on ASH 2021 - An Expert Discussion. Invited. Journal of Immunotherapy and Precision Oncology. Virtual, US.
2021. Novel targeted agents in clinical trials for MPN. Invited. Alpine Oncology Foundation. Virtual, US.
2021. Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Invited. 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Atlanta, GA, US.
2021. Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement. Invited. 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Atlanta, GA, US.
2021. Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. Invited. 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Atlanta, GA, US.
2021. Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies. Invited. 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Atlanta, GA, US.
2021. Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Pediatric Patients with Tagraxofusp, a CD123-Targeted Therapy. Invited. 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Atlanta, GA, US.
2021. Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Atlanta, GA, US.
2021. Completely Beyond JAKi (CD123 with SL401). Invited. Remedy Health Media. Virtual, US.
2021. Current Data on Navitoclax: Targeting BCL-2/BCL-xL in Myelofibrosis. Invited. Dave Oncology. Virtual, US.
2021. Navitoclax mechanism and Refine phase 2 data. Invited. AbbVie. Virtual, US.
2021. JAKi therapy and other emerging novel therapies for myelofibrosis. Invited. BinayTara Foundation. Virtual, UT, US.
2021. Advances In CAR T-Cell Therapy. Invited. Leukemia and Lymphoma Society (LLS). Virtual, US.
2021. Case Presentations in Myelofibrosis (MF). Invited. Physicians’ Education Resource, LLC (PER). Virtual, US.
2021. Toxicity Mitigation in CML Therapy. Invited. Imedex. Virtual, US.
2021. Novel Therapies for MPNs with a Focus on CMMoL. Invited. Imedex. Virtual, US.
2021. Poster #150: Outcomes of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Who Received Hematopoietic Stem Cell Transplantation Following Remission Induction with Tagraxofusp, a Targeted Therapy Directed to CD123. Conference. Stemline Therapeutics. Virtual, US.
2020. Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Conference. 62nd ASH Annual Meeting & Exposition. Virtual, US.
2020. The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. Conference. 62nd ASH Annual Meeting & Exposition. Virtual, US.
2020. Current and Emerging Strategies for BPDCN. Invited. 38th Annual Chemotherapy Foundation Symposium (CFS): Innovative Cancer Therapy for Tomorrow. Virtual, US.
2020. Rare Diseases: Blastic Plasmacytoid Dendritic Cell Neoplasm. Invited. Imedex. Virtual, US.
2020. Novel Agents in MPN Beyond JAK inhibitors. Invited. Alpine Oncology Foundation. Virtual, US.
2020. Case Studies in Blastic Plasmacytoid Dendritic Cell Neoplasm: Tackling the Diagnostic Challenge. Invited. Stemline Therapeutics. Virtual, US.
2020. Interim Results from an Ongoing Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Chronic Myelomonocytic Leukemia (CMML). Conference. Society of Hematologic Oncology (SOHO). Houston, TX, US.
2020. Updated Results from a Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Myelofibrosis. Conference. Society of Hematologic Oncology (SOHO). Houston, TX, US.
2020. Tagraxofusp, a CD123-Targeted Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Results of a Landmark Clinical Trial. Conference. Society of Hematologic Oncology (SOHO). Houston, TX, US.
2020. Treatment of Chronic Idiopathic Myelofibrosis. Invited. Imedex. New York, NY, US.
2020. What is the Main Objective of Therapy in CML? Improve Survival Endpoints. Invited. Imedex. New York, NY, US.
2020. Treatment Approach for Aggressive Myeloproliferative Neoplasms. Conference. Imedex. New York, NY, US.
2020. Session VIII: Q&A Keynote: How has the pandemic affected treatment of Hemotologic Malignancies in NY?. Conference. Imedex. New York, NY, US.
2020. Therapeutic Landscape of MPN and MDS: What to Do After Ruxolitinib Failure. Invited. DAVA Oncology, (OMI) Oncology Meeting Innovations. Irving, TX, US.
2020. Updates and Novel Therapies in BPDCN. Invited. University of Miami Health System, Sylvester Comprehensive Cancer Center. Miami, FL, US.
2019. Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2019. Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2019. Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2019. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2019. Myeloproliferative Neoplasm (MPN) Patient Online Questionnaire: Assessing Patients’ Disease Knowledge in a Rare Hematologic Malignancy in the Modern Digital Information Era. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2019. Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2019. Data on Treatment Options for Myelofibrosis. Invited. Amerisource Bergen. San Francisco, CA, US.
2019. Chronic Myeloid Leukemia (CML). Invited. Leukemia & Lymphoma Society. San Antonio, TX, US.
2019. ASH Committee on Communications. Invited. ASH Committee, WA, US.
2016. Outcome of Patients with Philadelphia Chromosome-Negative Acue Lymphoblastic Leukemia (ALL) By Age Group of er 35 Years: A Single Institution Experience. Conference. Outcome of Patients with Philadelphia Chromosome-Negative Acue Lymphoblastic Leukemia (ALL) By Age Group of er 35 Years: A Single Institution Experience. San Diego, CA, US.
2016. Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Conference. ASH 2016 Annual Meeting. San Diego, CA, US.
2014. Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). Invited. 56th Annual Meeting American Society of Hematology. San Francisco, CA, US.
2011. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia, oral presentation. Invited. 2011 Chronic Lymphocytic Leukemia Young Investigators' Meeting. Houston, TX, US.
2011. Dasatinib as initial therapy for patients with chronic myeloid leukemia in early chronic phase, oral presentation. Invited. Mini-Symposia American Association for Cancer Research. Orlando, FL, US.
2010. Retrospective review of male breast cancer patients: analysis of tamoxifen-relted side effects, poster presentation. Conference. 33rd Annual Meeting San Antonio Breast Cancer Symposium. San Antonio, TX, US.
2008. Overactive bladder, underactive bowel: solifenacin-associated small bowel pseudo-obstruction, poster presentation. Conference. Society of Hospital Medicine Annual Meeting. San Diego, CA, US.
2008. A green apple in the chest: amyloidosis, poster presentation. Conference. 31st Annual Meeting Society of General Internal Medicine. Pittsburgh, PA, US.
2006. Heterogeneous JAK2V617F allele burden in essential thrombocytosis: gender and clinical correlates, oral presentation. Invited. 48th Annual Meeting American Society of Hematology. Orlando, FL, US.
2005. Osler's aequanimitas in the twenty-first century, oral presentation. Invited. 7th Annual Meeting of Southern Association for History of Medicine and Sciences. Atlanta, GA, US.

International Presentations

2023. Updates in diagnosis, pathogenesis, and future directions in BPDCN. Invited. VJHemeOnc. San Diego, US.
2023. Bench to bedside in MPNs – 10 years of CALR. Invited. VJHemeOnc. San Diego, US.
2023. INTERIM ANALYSIS OF A REGISTRATION-ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN). Invited. European Hematology Association (EHA). Frankfurt, DE.
2023. Advances in Myelofibrosis: Exploring the Current and Evolving Treatment Landscape. Invited. Bristol Myers Squibb. Frankfurt, DE.
2023. Adolescents and Young Adults with Hematologic Malignancies: Patient Characteristics and Special Considerations. Invited. American Society of Clinical Oncology (ASCO). Chicago, US.
2023. Advances in the Diagnosis and Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. Saudi Society of Bone Marrow Transplantation (SSBMT). Riyadh, SA.
2023. Updates in Myeloproliferative Neoplasms. Invited. The ASCO Post. Virtual, US.
2023. Targeting CD123 in BPDCN. Invited. DAVA Oncology. Whistler, CA.
2023. Novel approaches to the treatment of myeloproliferative neoplasms. Invited. DAVA Oncology. Whistler, CA.
2023. MRD evaluation of AML in clinical practice, Is it ready and how to assess?. Invited. Emirates Medical Association. Virtual, GB.
2023. Using precision medicine to treat AML in 2023. Invited. Emirates Medical Association. Virtual, AE.
2023. How I treat Blastic Plasmacyyoid Dendretic Cell Neoplasm (BPDCN). Invited. Emirates Haematology Conference 2023. Virtual, AE.
2023. Evolving Diagnostic and Therapeutic Approaches in BPDCN. Invited. Menarini-UAE, SA.
2023. Combination Approaches for Myelofibrosis. Invited. Hôpital Saint Louis. Berlin, DE.
2023. Standard and novel therapies in MPN MYELOFIBROSIS Around the World. Invited. Philippine College of Hematology and Transfusion Medicine (PCHTM). Virtual, PH.
2022. Medical Session #4: Personalized medicine in MPNs - Oxford style debate: Late-stage Myelofibrosis. Transplant or not? No. Invited. MPN Advocates Network. Netanya, IL.
2022. Medical Session 2: Novel Therapies in MPNs - Past and Future of MPN Treatment. Invited. MPN Advocates Network. Netanya, IL.
2022. Medical Session 1: Challenges still exist in MPNs: Diagnosing MPNs. Invited. MPN Advocates Network. Netanya, IL.
2022. Combining Novel Agents for Treating Myelofibrosis. Invited. Melton Medical Education. Brooklyn, US.
2022. Pivekimab efficacy data from the AML triplet (802) and BPDCN (801) studies. Invited. Immunogen, Inc. Rome, IT.
2022. Tagraxofusp in 2022: State of the Art. Conference. Stemline Therapeutics. Rome, IT.
2022. How I manage BPDCN in MDACC. Invited. SOHO Italy: 2022 Annual Conference Hybrid Event. Rome, IT.
2022. A revolution in ultra-rare diseases: the example of BPDCN. Invited. 5th Annual Meeting of the International Academy for Clinical Hematology (IACH). Virtual, FR.
2022. TREATMENT OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PEDIATRIC PATIENTS WITH TAGRAXOFUSP, A CD123-TARGETED THERAPY. Invited. European Hematology Association (EHA). Virtual, Vienna, AT.
2022. RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS. Invited. CTI Biopharma, European Hematology Association (EHA). Virtual, Vienna, AT.
2022. Placing New MPN Therapies into Context Through Illustrated Case Discussions. Invited. Physician's Education Resource (PER). Chicago, US.
2022. Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF). Invited. American Society of Clinical Oncology (ASCO). Chicago, US.
2022. CONTROVERSIES IN MYELOFIBROSIS: DEFINING AND MEASURING DISEASE MODIFICATION. Invited. AbbVie. Virtual, Budapest, HU.
2022. Moderator for Q&A: Patient Case Presentations. Invited. Novartis. Virtual, Karel V, Utrecht, NL.
2022. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. Invited. The International Academy for Clinical Hematology (IACH). Virtual.
2022. Tagresofusp, BPDCN and its management. Invited. Stemline, Astellas. Virtual, GB.
2022. Co-Chair: Session 4 - OPEN STUDIES. Invited. Magdelen Medical Publishing. Virtual, US.
2022. Co-Chair: Session 1 – SCIENCE ADVANCES IN THE MPN FIELD. Invited. Magdelen Medical Publishing. Virtual, US.
2021. Clinical Management for BPDCN. Invited. Physicians' Education Resource, LLC (PER), MJH Life Sciences, Stemline Therapeutics, Inc. Virtual, US.
2021. Chronic MPN (Myeloproliferative Neoplasms) Update. Invited. Cleveland Clinic & Aplastic Anemia and MDS International Foundation, Friday Satellite Symposia: Resuscitating a Dying Marrow: Emerging Concepts and Treatment Advances in Myeloid Malignancies. Atlanta, US.
2021. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. Fondazione Internazionale Menarini, CONTATTO & ARCHIMEDICA Edizioni Scientifiche. Virtual, IT.
2021. New agents of potential value in the MPN. Invited. Melton Medical Education, LLC. Virtual, US.
2021. Co-Chair, Myelofibrosis External Experts Advisory Roundtable. Conference. CTI BioPharma. Virtual, US.
2021. How I manage BPDCN at MD Anderson Cancer Center. Invited. Society of Hematologic Oncology (SOHO) Italy. Virtual, IT.
2021. Taking the torch from discoverers: bring forth hope to hopeless patients with devastating neoplasms such as BPDCN. Invited. Society of Hematologic Oncology (SOHO) Italy, Stemline Therapeutics Switzerland GmbH. Virtual, IT.
2021. Quality of Life. Invited. Canadian Myeloproliferative Neoplasm (MPN) Network. Virtual, CA.
2021. BPDCN. Invited. International Academy for Clinical Hematology (IACH). Virtual, FR.
2021. Using and Sequencing JAK Inhibitors for Patients with Myelofibrosis. Invited. Bio Ascend. Virtual, US.
2021. Novel Treatment Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. Neopharm Israel. Virtual, IL.
2021. Novel insights into the biology and treatments of blastic plasmacytoid dendritic cell neoplasm. Invited. Menarini-Stemline. Virtual, NL.
2021. Navitoclax and Ruxolitinib Combination in Patients with Myelofibrosis. Invited. Bristol Myers Squibb. Virtual, NL.
2021. CD123-Targeting Antibody Drug Conjugate (ADC) Monotherapy for Blastic Plasmacytoid Dendritic Cell Neopalsm (BPDCN). Invited. DAVA Oncology. Virtual, CA.
2021. How I Treat Myelofibrosis (MF) in Lower/Intermediate Risk Patients. Invited. NOVARTIS. Virtual, CO.
2021. Meet the Expert Session – How to safely and successfully use social media in medicine. Invited. European School of Hematology (ESH). Virtual, FR.
2021. Interactive case: Blastic plasmacytoid dendritic cell neoplasms. Invited. European School of Hematology (ESH). Virtual, FR.
2021. Session IV, Novel Therapies in AML & BPDCN: Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. The Scientific Committee of the International Workshop on Acute Leukemias (iwAL). Virtual, US.
2020. Social media in hematology and focus on MPN - Highlighting rare diseases and our research and #MPNSM. Invited. European Hematology Association (EHA). Frankfurt, DE.
2020. Updated Results from a Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, In Patients with Poor-Risk Myelofibrosis. Invited. European Hematology Association (EHA). Frankfurt, DE.
2020. Tagraxofusp (SL-401), a CD123-Directed Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Genomic Landscape and Long-Term Results of a Landmark Clinical Trial. Invited. European Hematology Association (EHA). Frankfurt, DE.
2019. Novel Therapies in MPN Clinical Trials - Beyond JAK Inhibitors. Invited. MPN Advocacy & Education International. Cleveland, US.
2019. Novel Agents of Significant Clinical Interest in the MPNs. Invited. 12th International Congress on Myeloproliferative Neoplasms (MPN). New York, US.
2019. Session Chair for Myeloid Diseases: Non-Transplant Approaches. Invited. 2nd Annual Meeting of the International Academy for Clinical Hematology (IACH). Paris, FR.
2019. Allogeneic Stem Cell Transplant Indications and Results. Invited. 2nd Annual Meeting of the International Academy for Clinical Hematology (IACH). Paris, FR.
2019. Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes and Allotransplant. Invited. 2019 Best of ASCO Baltimore Meeting. Baltimore, US.
2019. Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Conference. 24th EHA Congress. Amsterdam, NL.
2019. Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes and Allotransplant. Conference. ASCO 2019 Annual Meeting. Chicago, US.
2019. MasterClass and Case Forum Changing the Treatment Story in Myelofibrosis: New Science and More Choices for Challenging Cases in the JAK Inhibitor Era. Invited. Medical Learning Institute, Inc. and PeerView. Chicago, US.
2018. Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. Invited. European Hematology Association (EHA). Stockholm, SE.
2018. 5th Annual Summit on Hematologic Malignancies. Invited. DAVA Oncology. Whistler, CA.
2018. Social media and myeloproliferative neoplasms-focus on twitter and th development of a disease specific community. Invited. I International Symposium of Onco-Hematology. Sao Paulo, BR.
2017. Social Media for connecting doctors: the Myeloproliferative neoplasms (MPNs) model. Invited. EBMT 2017 Annual Meeting. Marseille, FR.
2016. Phase II Study of LCL161, A Smac Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF). Conference. EHA - 21st Congress. Copenhagen, DK.
2016. Results from Phase 2 Registration Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Conference. ASCO 2016 Annual Meeting. Chicago, US.
2012. Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) treated with Second generation Tyrosine kinase inhibitors (TKI) dasatinib and Nilotinib poster presentation. Conference. ESH 4th International Conference CML - Biology and Therapy. Baltimore, US.
2011. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia, poster presentation. Conference. Fourteenth International Workshop on Chronic Lymphocytic Leukemia. Houston, US.
2010. FLT3 inhibitors in acute myeloid leukemia: era of Personalized therapy in AML, oral presentation. Invited. Global Academic Programs Conference of Fellow's Exchange. Cancun, MX.

Formal Peers

2023. Chronic Myeloid Leukemia (CML) 101. Visiting. Houston, TX, US.
2023. Introduction to Myeloproliferative Neoplasms (MPNs) 101. Visiting. Houston, TX, US.
2023. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in 2023 and Beyond: Lessons Learned from Investigating an Ultra-Rare Hematology Malignancy. Visiting. Salt Lake City, UT, US.
2023. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in 2023 and Beyond: Lessons Learned from Investigating an Ultra-Rare Hematology Malignancy. Visiting. New York, NY, US.
2023. Case Conference with Dr. Dillard and Dr. Pemmaraju - BPDCN. Visiting. Houston, TX, US.
2022. Novel Therapeutic Combinations in Myelofibrosis: Focus on Targeting BCLxL in MPNs and Beyond. Visiting. Houston, TX, US.
2022. Chronic Myeloid Leukemia (CML) 101. Visiting. Houston, TX, US.
2022. Introduction to Myeloproliferative Neoplasms (MPNs): MPN 101. Visiting. Houston, TX, US.
2022. Blastic Phasmacytoid Dendritic Cell Neoplasm (BPDCN): Updates and Future Directions for 2022 & Beyond. Visiting. Houston, TX, US.
2022. BPDCN. Visiting. Aurora, CO, US.
2022. Targeting BCL-xL with Navitoclax in Myelofibrosis: An Emerging Area. Visiting. Houston, TX, US.
2022. Focusing on An Ultra-Rare Disease: Lessons Learned in Development of Novel Approaches for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Visiting. Virtual, US.
2022. Introduction to BPDCN diagnosis, treatment, and management. Visiting. Houston, TX, US.
2021. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Lessons learned from studying and ultra-rare disease. Invited. Virtual, MI, US.
2021. Resident and Fellows Lecture: BPDCN. Invited. Virtual, IN.
2021. Mortality and Morbidity Case Study. Visiting. Houston, TX, US.
2021. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Visiting. Houston, TX, US.
2021. Grand Rounds for Fred Hutch: Novel Therapeutic Approaches in Blastic Plasmcytoid Dendritic Cell Neoplasm (BPDCN): Targeting CD123 and Beyond. Invited. Virtual, WA, US.
2021. RUXO + Navitoclax/BCLXL in MPN. Visiting. Houston, TX, US.
2020. Introduction to Myeloproliferative Neoplasms (MPNs): MPN 101. Visiting. Houston, TX, US.
2020. Chronic Myeloid Leukemia (CML). Visiting. Houston, TX, US.
2020. Novel Therapies and Future Directions in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. Iowa City, IA, US.
2020. Novel Therapies and Future Directions in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. Denver, CO, US.
2019. Levine Cancer Institute Grand Rounds: Updates and Developments in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) - State of the Art for 2020 and Beyond. Invited. Charlotte, NC, US.
2019. Medical Grand Rounds: Novel Agents Beyond JAK inhibitors in Treatment of Patients with MPNs. Invited. Durham, NC, US.
2019. Medical Grand Rounds: Updates and Developments in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) - State of the Art for 2020 and Beyond. Invited. Buffalo, NY, US.
2019. Updates and Progress in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in the Era of Novel/Targeted Therapies in 2019 and Beyond. Invited. Miami, FL, US.
2019. Cancer Center Grand Rounds: BPDCN - Era of Targeted Therapy in 2019 and Beyond. Invited. Phoenix, AZ, US.
2016. State of the Art: Update for BPDCN in 2016. Visiting. Houston, TX, US.
2010. Outcomes with FLT3 inhibitors: personalized targeted therapy for acute myeloid leukemia. Visiting. Houston, TX, US.
2010. Hematology/Oncology Board Review Series (3 lectures). Invited. Houston, TX, US.

Less

Grant & Contract Support

Date:	2023 - 2028
Title:	SPORE University of Texas M.D. Anderson Cancer Center-Leukemia
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2 P50 CA100632-21A1 / PAR-20-305 / FP00015698_Res1

Date:	2023 - 2026
Title:	Characterizing cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm
Funding Source:	Dermatology Foundation
Role:	Mentor
ID:	FP00018083: Medical Dermatology Career Development Award

Date:	2023 - Present
Title:	A phase 1b study of ABBV-744 alone or in combination with Ruxolitinib or Navitoclax in subjects with myelofibrosis
Funding Source:	AbbVie
Role:	PI
ID:	2022-1084

Date:	2023 - 2024
Title:	A Phase 1b Study of ABBV-744 Alone or in Combination with Ruxolitinib or Navitoclax in Subjects with Myelofibrosis
Funding Source:	AbbVie
Role:	PI
ID:	2022-1084

Date:	2022 - 2024
Title:	Phase 1 Evaluation of the Safety and Pharmacokinetics of First-in-class N-myristoylation Inhibitor, PCLX-001, in Patients with Relapsed/Refractory Acute Myeloid
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	FP#14594

Date:	2022
Title:	A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera
Funding Source:	Protagonist Therapeutics, Inc
Role:	PI
ID:	2022-0005

Date:	2022 - 2023
Title:	A phase I multi-dose study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) with or without recombinant human Interleukin-2 (rhIL-2)in adults with primary or secondary (AML) in morphologic complete remission
Funding Source:	Cellularity, Inc
Role:	PI
ID:	2021-0718 / CYNK-001-AML-001

Date:	2022 - 2039
Title:	A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients with Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, and High Risk Myelodysplastic Syndrome
Funding Source:	MustangBio, Inc
Role:	PI
ID:	2019-0097 / MB102-CD123-001

Date:	2022 - 2036
Title:	A Long-term Follow-up Study in Patients Previously Treated with Mustang Bio, Inc. CAR-T Cell Investigational Products
Funding Source:	MustangBio, Inc
Role:	PI
ID:	2021-0314 / MB100-OBS-001

Date:	2022 - 2026
Title:	NO TITLE PROVIDED
Funding Source:
Role:

Date:	2021 - 2022
Title:	Single-cell resolution of Blastic Plasmacytoid Dendritic Cell Neoplasm Clonal Heterogeneity
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	W81XWH-20-RCRP-CA

Date:	2021 - 2025
Title:	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Funding Source:	AbbVie
Role:	PI
ID:	2020-0743 / M16-191

Date:	2021 - 2022
Title:	Phase Ib/II Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Funding Source:	Ascentage Pharma Group Inc
Role:	PI
ID:	2020-0814 / APG1252MU101

Date:	2021 - 2021
Title:	A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects with Relapsed or Refractory AML
Funding Source:	Janssen Pharmaceutical Companies of Johnson & Johnson
Role:	PI
ID:	2019-0911 / 63709178AML1001

Date:	2020 - 2027
Title:	Telios Pharma, Inc
Funding Source:	Telios Pharma, Inc
Role:	PI
ID:	2020-0738

Date:	2020 - 2024
Title:	Identifying Novel Therapeutic Targets and Combination Strategies for Patients with BPDCN
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	W81XWH2010683 / USAMRAA

Date:	2020 - 2022
Title:	Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (>/= 60 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Funding Source:	Rafael Pharmaceuticals
Role:	PI
ID:	2019-0014 / AML003

Date:	2020 - 2026
Title:	Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): SL-401 in combination with HCVAD and VENETOCLAX
Funding Source:	Stemline Therapeutics, Inc. / UT MD Anderson Cancer Center
Role:	PI
ID:	2019-0587

Date:	2020 - 2023
Title:	Nonclinical development of a novel dual JAK2/BET inhibitor for the treatment of myelofibrosis and other hematological malignancies
Funding Source:	Ohm Oncology
Role:	PI
ID:	RFA C-20.1-SEED

Date:	2019 - 2023
Title:	Phase 1b Study of PU-H71 for the Treatment of Subjects with Primary Myelofibrosis (PMF), Post- Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Treated with Ruxolitinib
Funding Source:	Samus Therapeutics
Role:	PI
ID:	2019-0019 / PU-H71-01-003

Date:	2019 - 2022
Title:	A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Funding Source:	Plexxikon
Role:	PI
ID:	2018-0932 / PLX124-02

Date:	2019 - 2022
Title:	A Phase I Study of PLX51107 (A Novel Bromodomain Inhibitor) in Combination with Azacytidine for Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia (AML)
Funding Source:	Daiichi-Sankyo / Plexxicon, Inc. / UT MD Anderson Cancer Center
Role:	PI
ID:	2018-0725

Date:	2019 - 2023
Title:	Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Funding Source:	Dana Farber Partners Cancer Care, Inc
Role:	PI
ID:	2018-0841 / 18-045

Date:	2019 - 2020
Title:	Disease knowledge of people with myeloproliferative neoplasms who participate in the Patient Power online community: feasibility and exploration
Funding Source:	Patient Power LLC
Role:	PI
ID:	2017-0846

Date:	2018 - 2019
Title:	Development of a Novel Symptom Burden Assessment Tool for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Funding Source:	Leukemia Texas
Role:	Principal Investigator-MDACC
ID:	FP#5163

Date:	2018 - 2023
Title:	Phase 1, Open Label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with Relapsed/Refractory Acute Myeloid Leukemia
Funding Source:	Cellectis S.A
Role:	PI
ID:	2017-0559 / UCART123_01

Date:	2018 - 2020
Title:	A Phase Ib Study of Ruxolitinib in Combination with PU-H71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), and Post-Essential Thrombocythemia MF (post-ET MF)
Funding Source:	Samus
Role:	PI
ID:	2017-0750 / PU-H71

Date:	2018 - 2024
Title:	Phase 1 Study of SL-401 in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia (AML) or in Treatment-Naive Subjects with AML Not Eligible for Standard Induction Therapy or in Subjects with High-Risk Myelodysplastic Syndrome (MDS)
Funding Source:	Dana Farber Partners Cancer Care, Inc. / Stemline Therapeutics, Inc
Role:	PI
ID:	2017-0354 / 17-056

Date:	2017 - 2023
Title:	A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis
Funding Source:	AbbVie
Role:	PI
ID:	2017-0495 / M16-109

Date:	2017 - 2019
Title:	Phase I, open label dose-escalation study to evaluate the safety, expansion, persistence and clinical activity of a single dose of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with BPDCN
Funding Source:	Cellectis
Role:	PI
ID:	2016-0840

Date:	2016 - 2017
Title:	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Molecular Characterization and Identification of Novel Therapeutic Approaches
Funding Source:	Ladies Leukemia League
Role:	PI

Date:	2016 - 2017
Title:	Integrative Genomic Profiling of Blastic Plasmacytoid Dendritic Cell Neoplasms
Funding Source:	MD Anderson Division of Pathology and Lab Medicine
Role:	Clinical Collaborator
ID:	Unknown

Date:	2016 - 2018
Title:	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Molecular Characterization and Identification of Novel Therapeutic Approaches
Funding Source:	MD Anderson Sabin Fellow Award
Role:	PI

Date:	2015 - 2023
Title:	SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms
Funding Source:	Stemline Therapeutics, Inc
Role:	PI
ID:	2014-0976 / STML-401-0314

Date:	2015 - 2027
Title:	A Study to Evaluate Patient Samples with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Funding Source:	Cellectis S.A., Moonshots Program, Affymetrix, Inc
Role:	PI
ID:	PA14-0157

Date:	2014 - 2022
Title:	Open Label Phase 2 Single agent study of LCL-161 in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Funding Source:	Novartis / UT MD Anderson Cancer Center
Role:	PI
ID:	2013-0612 / CLCL161AUS02T

Date:	2014 - 2016
Title:	Biomarker Analysis of Markers of Apoptosis in a Phase II Clinical Trial of a Novel, Second Mitochondria-Derived Activator of Caspase (Smac) Mimetic for Patients with Primary Myelofibrosis
Funding Source:	MDACC R. Lee Clark Fellows Award
Role:	PI
ID:	01

Date:	2014 - 2020
Title:	SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Funding Source:	Stemline Therapeutics, Inc
Role:	PI
ID:	2013-0979

Date:	2013 - 2016
Title:	2012 Clinical Scientist Development Award: Prospective Evaluation of Effects of Tyrosine Kinase Inhibitor (TKI) Dasatinib on Bone Formation and Changes in Bone Metabolism in Treatment of Patients with Chronic Myeloid Leukemia (CML)
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	PI
ID:	01

Date:	2013 - 2014
Title:	Biologic and Molecular Characterization of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Identification of Novel Therapeutic Targets
Funding Source:	Ladies Leukemia League
Role:	PI
ID:	01

Date:	2012 - 2013
Title:	2012 Clinical Scientist Development Award: Prospective Evaluation of Effects of Tyrosine Kinase Inhibitor (TKI) Dasatinib on Bone Formation and Changes in Bone Metabolism in Treatment of Patients with Chronic Myeloid Leukemia (CML)
Funding Source:	ASBMR
Role:	PI
ID:	JFOR201225

Title:	Genomic Characterization of Plasmacytoid Dendritic Cell (pDC)-Acute Myeloid Leukemia (AML): Identification of Novel Targeted Therapies
Funding Source:	The University of Texas MD Anderson Cancer Center, Institutional Research Grant (IRG) Program
Role:	PI
ID:	IRB April 2021, Application ID 1523

Selected Publications

Peer-Reviewed Articles

DiNardo CD, Jen WY, Montalban-Bravo G, Wang X, Loghavi S, Lavu S, Short NJ, Chien K, Issa GC, Pemmaraju N, Yilmaz M, Andreeff M, Borthakur G, Kadia TM, Daver NG, Garcia-Manero G, Mill CP, Su X, Fiskus W, Bhalla KN. Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1. Blood Neoplasia 2(4):100145, 2025. e-Pub 2025. PMID: 40979071.
Patnaik MM, Ali H, Wang ES, Yacoub A, Foran JM, Gupta V, Schiller GJ, Stevens DA, Talpaz M, Wall S, Lasho TL, Mangaonkar AA, Badar T, Lindsay R, Galleu A, Gupta I, Pemmaraju N, Garcia-Manero G. Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study. Blood Neoplasia 2(4):100115, 2025. e-Pub 2025. PMID: 40919483.
Croden J, Jen WY, Marvin-Peek J, Xiao L, Bouligny IM, Loghavi S, Borthakur G, Daver NG, Abbas HA, Takahashi K, Sasaki K, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Alvarado-Valero Y, Garcia-Manero G, Ravandi F, Konopleva MY, Kantarjian HM, Kadia TM, DiNardo CD. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. Leukemia 39(10):2538-2541, 2025. e-Pub 2025. PMID: 40813623.
Jen WY, Tang G, Kugler E, Croden J, Sasaki K, Bazinet A, Bataller A, Montalban-Bravo G, Borthakur G, Toruner GA, Loghavi S, Short NJ, Issa GC, Bouligny IM, Pierce S, Popat U, Pemmaraju N, Jabbour E, Garcia-Manero G, Bhalla K, Ravandi F, Daver NG, DiNardo CD, Kantarjian HM, Kadia TM. MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia. Br J Haematol, 2025. e-Pub 2025. PMID: 40983567.
Fiskus W, Masarova L, Mill CP, Birdwell C, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Manshouri T, Dunbar A, Sharma S, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Su X, Rampal RK, Torngren M, Bhalla KN. Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phase. Blood Adv, 2025. e-Pub 2025. PMID: 40829105.
Senapati J, Kantarjian HM, Kadia TM, Kekedjian J, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Short NJ, Yilmaz M, Jain N, Pemmaraju N, Abbas HA, Issa GC, Maiti A, Bravo GM, Deshmukh I, Shpall E, Kebriaei P, Popat U, Loghavi S, Thakral B, Tang G, Haddad FG, Alvarado Y, Manero GG, Ravandi F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16):e70028, 2025. e-Pub 2025. PMID: 40772501.
Arora S, Jen WY, Yilmaz M, Deshmukh I, Senapati J, Loghavi S, Issa GC, Short NJ, Kadia TM, DiNardo CD, Borthakur G, Jabbour J, Pemmaraju N, Andreeff M, Takahashi K, Bhalla K, Popat U, Shpall EJ, Oran B, Abbas HA, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation. Cancer 131(16):e70032, 2025. e-Pub 2025. PMID: 40782343.
Bazinet A, Loghavi S, Wei Y, Bataller A, Sasaki K, Arani N, Darbaniyan F, Chien K, Hammond D, Bouligny I, Kanagal-Shamanna R, Thongon N, Tang G, Urrutia S, Kadia T, DiNardo C, Daver N, Short N, Issa G, Pemmaraju N, Jabbour E, Wang SA, Wang W, Borthakur G, Bueso-Ramos C, Ravandi F, Medeiros LJ, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy. Leukemia 39(9):2256-2265, 2025. e-Pub 2025. PMID: 40691503.
Montalban-Bravo G, Loghavi S, Li Z, Chien KS, Kanagal-Shamanna R, Bataller A, Natu A, Gurney M, Bazinet A, Hammond D, Sasaki K, Borthakur G, Swaminathan M, DiNardo CD, Kadia TM, Ravandi F, Daver NG, Short NJ, Pemmaraju N, Issa GC, Lasho TL, Finke CM, Al-Kali A, Csizmar CM, Alkhateeb HB, Gangat N, Mangaonkar AA, Bueso-Ramos CE, Tefferi A, Kantarjian HM, Garcia-Manero G, Patnaik MM. Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia. Blood Adv, 2025. e-Pub 2025. PMID: 40644618.
Uryu H, Saeki K, Haeno H, Kapadia CD, Furudate K, Nangalia J, Spencer Chapman M, Zhao L, Hsu JI, Zhao C, Chen S, Tanaka T, Li Z, Ogata S, Hanache S, Yang H, DiNardo C, Daver N, Pemmaraju N, Jain N, Ravandi F, Zhang J, Song X, Thompson E, Tang H, Little L, Gumbs C, Orlowski RZ, Qazilbash M, Bhalla K, Colla S, Kantarjian H, Kanagal-Shamanna R, Bueso-Ramos C, Nakada D, Al-Atrash G, Molldrem J, Futreal PA, Shpall E, Goodell M, Garcia-Manero G, Takahashi K. Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation. Nat Genet 57(7):1695-1707, 2025. e-Pub 2025. PMID: 40596442.
Pemmaraju N, Yu J, Vasudevan A, Qureshi H, Braunstein E, Chojecki A. Treatment patterns and blood count control in 10,112 patients with polycythemia vera. Expert Rev Hematol 18(7):529-536, 2025. e-Pub 2025. PMID: 40512071.
Croden J, Pemmaraju N, Fliehler K, Brown A, Wang W, Kantarjian H, Vega F, Kadia T. Managing BPDCN in the context of severe hyperbilirubinemia: a case study. Leuk Lymphoma:1-4, 2025. e-Pub 2025. PMID: 40569706.
Csizmar CM, Natu A, Gurney M, Fathima S, Alsugair AKA, Kanagal-Shamanna R, Loghavi S, Bazinet A, Chien K, Hammond D, DiNardo C, Kadia T, Ravandi-Kashani F, Pemmaraju N, Sasaki K, Lasho TL, Finke CM, Al-Kali A, Alkhateeb H, Begna K, Gangat N, Hefazi Torghabeh M, Matin A, Mangaonkar AA, Saliba AN, Tefferi A, Garcia-Manero G, Kantarjian HM, Komrokji RS, Xie Z, Ali NA, Sallman D, Padron E, Montalban-Bravo G, Patnaik MM. Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. Leukemia 39(8):2030-2034, 2025. e-Pub 2025. PMID: 40555734.
DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. J Clin Oncol 43(24):JCO2500640, 2025. e-Pub 2025. PMID: 40513054.
Azevedo RS, Fayad L, Kanagal-Shamanna R, Loghavi S, Hu S, Bueso-Ramos CE, Sasaki K, Abuasab T, Khawaja F, Goulart H, Abou Dalle I, Borthakur G, Pemmaraju N. Treatment of RAS-associated leukoproliferative disease (RALD) and Rosai-Dorfman disease in a patient with KRAS mutation. Leuk Lymphoma:1-5, 2025. e-Pub 2025. PMID: 40440732.
Kadia TM, Jen WY, Bataller A, Bazinet A, Borthakur G, Jabbour E, Qiao W, Short NJ, Takahashi K, Issa GC, DiNardo CD, Montalban-Bravo G, Pemmaraju N, Tran A, Bharathi V, Loghavi S, Alousi AM, Popat U, Daver NG, Ravandi F, Kantarjian HM. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. Am J Hematol 100(8):1365-1373, 2025. e-Pub 2025. PMID: 40401707.
Goulart H, Jabbour E, Short NJ, Kadia TM, Pemmaraju N, Takahashi K, Ravandi F, Konopleva M, Jain N. A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk, 2025. e-Pub 2025. PMID: 40500616.
Pemmaraju N, Phan LH, Fell G, Luskin MR, Swaminathan M, Pierce S, DiNardo C, Maiti A, Konopleva M, Lane AA. Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN. Blood Neoplasia 2(2):100086, 2025. e-Pub 2025. PMID: 40453135.
Sasaki K, Garcia-Manero G, Nigo M, Jabbour E, Ravandi F, Wierda WG, Jain N, Takahashi K, Montalban-Bravo G, Daver NG, Thompson PA, Pemmaraju N, Kontoyiannis DP, Sato J, Karimaghaei S, Soltysiak KA, Raad II, Kantarjian HM, Carter BW. Artificial Intelligence Assessment of Chest Radiographs for COVID-19. Clin Lymphoma Myeloma Leuk 25(5):319-327, 2025. e-Pub 2025. PMID: 39710565.
Goulart H, Garcia-Manero G, Kadia TM, Daver N, DiNardo CD, Ravandi F, Qazilbash M, Rausch C, Llaurador Caraballo G, Pierce S, Pemmaraju N. A case series of oral decitabine-cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm. Leuk Lymphoma:1-4, 2025. e-Pub 2025. PMID: 40304131.
Goulart, H, Kantarjian, HM, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Pemmaraju, N, Alvarado, Y, Atluri, H, Yilmaz, M, Haddad, FG, Marx, K, Rausch, C, Loghavi, S, Jain, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia. Cancer 131(8), 2025. e-Pub 2025. PMID: 40193193.
Goulart H, Kantarjian H, Borthakur G, Daver N, DiNardo CD, Jabbour E, Pemmaraju N, Alvarado Y, Atluri H, Yilmaz M, Haddad FG, Marx KR, Rausch C, Loghavi S, Jain N, Garcia-Manero G, Ravandi-Kashani F, Kadia TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial. Cancer 131(8):e35840, 2025. e-Pub 2025. PMID: 40193193.
Daver N, Senapati J, Kantarjian HM, Wang B, Reville PK, Loghavi S, Yilmaz M, DiNardo CD, Kadia TM, Yassouf MY, Maiti A, Arora S, Montalban Bravo G, Tang G, Borthakur G, Sasaki K, Pemmaraju N, Alvarez J, Nogueras Gonzalez GM, Ning J, Issa GC, Konopleva M, Andreeff M, Ravandi F, Garcia-Manero G, Abbas HA. Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis. Clin Cancer Res 31(12):2386-2398, 2025. e-Pub 2025. PMID: 40198272.
Wang Z, Skwarska A, Poigaialwar G, Chaudhry S, Rodriguez-Meira A, Sui P, Olivier E, Jia Y, Gupta V, Fiskus W, Ramage CL, Zheng G, Schurer A, Gritsman K, Papapetrou EP, Bhalla KN, Zhou D, Mead AJ, Rampal RK, Tyner JW, Abbas HA, Pemmaraju N, Tatarata QZ, Konopleva MY. Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AML. Blood 146(3):341-355, 2025. e-Pub 2025. PMID: 40163809.
Nanduri AC, Ashraf F, Hlaing SS, Brister M, Kadia TM, Pemmaraju N, Budak-Alpdogan T. Acute Promyelocytic Leukemia Presenting with Cranial Nerve Involvement and Clivus Mass. Acta Haematol:1-15, 2025. e-Pub 2025. PMID: 40159328.
Polverelli N, Hernandez-Boluda JC, Onida F, Gurnari C, Raj K, Czerw T, Kenyon M, Robin M, Sockel K, Ruggeri A, Sanchez-Ortega I, Arber DA, Arcaini L, Duarte FB, Battipaglia G, Chalandon Y, Ciceri F, Cross NCP, Drozd-Sokolowska J, Funke VAM, Gagelmann N, Gangat N, Gotlib J, Guglielmelli P, Harrison CN, Hobbs GS, Jain T, Khoury JD, Kiladjian JJ, Kroger N, Malcovati L, Martino M, Mesa R, Orazi A, Padron E, Palandri F, Passamonti F, Patnaik MM, Pemmaraju N, Radia DH, Reiter A, Russo D, Scheid C, Tefferi A, Vannucchi AM, Wiseman DH, Yakoub-Agha I, McLornan DP. Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Blood 145(22):2561-2573, 2025. e-Pub 2025. PMID: 40106773.
Pemmaraju N, Konopleva M, Sweet KL, Stein AS, Rizzieri DA, Wang ES, Vasu S, Rosenblat TL, Tosolini A, Gupta I, Lane AA. Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial. Leuk Lymphoma:1-4, 2025. e-Pub 2025. PMID: 40067964.
Chien KS, Curry JL, Pemmaraju N, Jain N. Leukemia Cutis in the Setting of Indolent Chronic Lymphocytic Leukemia. Am J Hematol 100(7):1240-1241, 2025. e-Pub 2025. PMID: 40062658.
Wei Q, Toruner GA, Thakral B, Patel KP, Pemmaraju N, Wang SA, Kanagal-Shamanna R, Tang G, Issa GC, Loghavi S, Medeiros LJ, DiNardo C. Cryptic KMT2A::AFDN Fusion Due to AFDN Insertion into KMT2A in a Patient with Acute Monoblastic Leukemia. Genes (Basel) 16(3), 2025. e-Pub 2025. PMID: 40149468.
DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
Pemmaraju N, Loghavi S. Blastic plasmacytoid dendritic cell neoplasm in the absence of cutaneous involvement. Blood 145(8):898, 2025. e-Pub 2025. PMID: 39976942.
Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau S, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica 110(7):1628-1633, 2025. e-Pub 2025. PMID: 39973365.
Senapati J, Loghavi S, Marvin-Peek J, Garcia-Manero G, Kadia TM, Borthakur G, Daver N, Short NJ, Jain N, Issa GC, Haddad F, Hammond D, Chien K, Tang G, Thakral B, Montalban-Bravo G, Pemmaraju N, Bazinet A, Swaminathan M, Pierce S, Abbas HA, Reville P, Popat U, Shpall E, Champlin R, Jabbour E, Ravandi F, Kantarjian HM, DiNardo CD. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies. Am J Hematol 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
Yu J, Gayle J, Rosenthal N, Brown H, Braunstein E, Pemmaraju N. Resource utilization and inpatient hospitalization costs associated with thromboembolic events among patients with polycythemia vera. Oncologist 30(2), 2025. e-Pub 2025. PMID: 40037619.
Pemmaraju N, Somervaille TCP, Palandri F, Harrison C, Komrokji RS, Perkins A, Ayala Diaz RM, Lavie D, Tomita A, Feng Y, Qin Q, Harb J, Polepally AR, Potluri J, Garcia JS. Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response. Blood Neoplasia 2(1):100056, 2025. e-Pub 2025. PMID: 40454409.
Kantarjian H, Short NJ, Jain N, Haddad FG, Kadia T, Yilmaz M, Ferrajoli A, Sasaki K, Alvarado Y, Pemmaraju N, Senapati J, Garris R, Ravandi F, Jabbour E. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Am J Hematol 100(3):402-407, 2025. e-Pub 2025. PMID: 39757533.
Park, GS, Atluri, H, DiNardo, C, Guillroy, B, Horak, J, Apostolidou, E, Buni, M, Montalban Bravo, G, Pemmaraju, N. Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies. Leukemia Research Reports 23, 2025. e-Pub 2025. PMID: 39691506.
Bashir, Q, Konopleva, M, Abueg, G, Ramdial, JL, Hosing, C, Srour, S, Alousi, AM, Popat, UR, Nieto, Y, Al-Atrash, G, Champlin, RE, Shpall, E, Qazilbash, MH, Pemmaraju, N. Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm. Leukemia Research Reports 24, 2025. e-Pub 2025. PMID: 40612021.
Krah NM, Hoeg R, Shami PJ, Elf SE, Lee LE, Pemmaraju N, Patel AB. Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base. Leuk Res Rep 24:100541, 2025. e-Pub 2025. PMID: 40917153.
Park GS, Atluri H, DiNardo CD, Guillroy B, Horak J, Apostolidou E, Buni M, Bravo GM, Pemmaraju N. Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies: A case report. Leuk Res Rep 23:100485, 2025. e-Pub 2025. PMID: 39691506.
Nahmod KA, Miranda RN, Vega F, Thakral B, Pemmaraju N, Montalban-Bravo G, Loghavi S, Jelloul FZ, Wang W, Wang S, Muzzafar T, Patel K, Bueso-Ramos CE, Medeiros LJ, Kanagal-Shamanna R. Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation: report of two cases with literature review. Leuk Lymphoma 66(4):1-9, 2024. e-Pub 2024. PMID: 39704386.
Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2024. e-Pub 2024. PMID: 39665206.
Pemmaraju N. BPDCN: state of the art. Hematology Am Soc Hematol Educ Program 2024(1):279-286, 2024. e-Pub 2024. PMID: 39644068.
Haddad FG, Sasaki K, Senapati J, Xiao L, Park G, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Ong F, Desikan S, Pemmaraju N, Loghavi S, Borthakur G, DiNardo C, Abbas HA, Short NJ, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia T. Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract 20(12):1637-1644, 2024. e-Pub 2024. PMID: 39013130.
Jen WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, Wierda W, Kadia TM, Daver NG, DiNardo CD, Short NJ, Jain N, Ferrajoli A, Kornblau S, Yilmaz M, Ohanian M, McCue D, Burger J, Hammond D, Patel K, Issa GC, Pemmaraju N, Sasaki K, Maiti A, Abbas HA, Chien K, Takahashi K, Haddad F, Bose P, Masarova L, Montalban-Bravo G, Swaminathan M, Brandt M, Pierce S, Garcia-Manero G, Ravandi F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2024. e-Pub 2024. PMID: 39584789.
Goulart H, Kantarjian H, Pemmaraju N, Daver N, DiNardo CD, Rausch CR, Ravandi F, Kadia TM. Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia. Blood Cancer Discov 6(1):OF1-OF15, 2024. e-Pub 2024. PMID: 39565177.
Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, Birdwell C, Davis JA, Das K, Hou H, Manshouri T, Jain A, Malovannaya A, Philip K, Alhamadani N, Matthews A, Lin K, Flores L, Loghavi S, DiNardo CD, Su X, Rampal RK, Bhalla KN. Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood 145(6):612-624, 2024. e-Pub 2024. PMID: 39561280.
Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Pemmaraju N, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal R, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39(2):524-528, 2024. e-Pub 2024. PMID: 39551874.
Urrutia S, Kantarjian HM, Ravandi-Kashani F, Bueso-Ramos C, Kanagal-Shamanna R, Jabbour E, Montalban-Bravo G, Short NJ, Daver N, Borthakur G, Dinardo CD, Kadia TM, Masarova L, Bose P, Pemmaraju N, Garcia-Manero G, Sasaki K. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. J Hematol Oncol 17(1):112, 2024. e-Pub 2024. PMID: 39548557.
Phan, L, Jabbour, EJ, Antonoff, MB, Jain, N, Lin, P, Moran, C, Pemmaraju, N. Unexpected Mediastinal Mass Etiology in B-Acute Lymphoblastic Leukemia. Journal of Immunotherapy and Precision Oncology 7(4):314-316, 2024. e-Pub 2024. PMID: 39524462.
Phan L, Jabbour E, Antonoff MB, Jain N, Lin P, Moran C, Pemmaraju N. Unexpected Mediastinal Mass Etiology in B-Acute Lymphoblastic Leukemia. J Immunother Precis Oncol 7(4):314-316, 2024. e-Pub 2024. PMID: 39524462.
Kharfan-Dabaja MA, Lane AA, Pemmaraju N. How I treat Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood 145(6):567-576, 2024. e-Pub 2024. PMID: 39374520.
Nasnas P, Ling J, Gerstein Y, Wang SA, Loghavi S, Hammond D, Montalban-Bravo G, Senapati J, Pemmaraju N, Corredor J, Pierce S, Roth M, Ravandi F, Cuglievan B, Kadia T, DiNardo CD. Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk 24(10):732-735, 2024. e-Pub 2024. PMID: 38945779.
DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, Verma A, Konopleva M. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer 5(10):1515-1533, 2024. e-Pub 2024. PMID: 39300320.
Short NJ, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa GC, Abbas H, Nasnas C, Qiao W, Huang X, Borthakur G, Chien K, Haddad FG, Pemmaraju N, Karrar OS, Nguyen D, Konopleva M, Kantarjian H, Ravandi F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol 11(11):e839-e849, 2024. e-Pub 2024. PMID: 39303729.
Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda JC, Bose P, Dohner K, Ellis M, Gangat N, Garcia JS, Gisslinger H, Gotlib J, Guglielmelli P, Gupta V, Harrison CN, Hexner EO, Hobbs GS, Kiladjian JJ, Koschmieder S, Kroger N, Kuykendall AT, Loscocco GG, Mascarenhas JO, Masarova L, Mesa R, Mora B, Odenike O, Oh ST, Pardanani AD, Patel AA, Pemmaraju N, Rambaldi A, Rampal RK, Sirhan S, Szuber N, Talpaz M, Vachhani P, Vannucchi AM, Barbui T. Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis. Blood 144(17):1813-1820, 2024. e-Pub 2024. PMID: 39116296.
Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer 130(15):2652-2659, 2024. e-Pub 2024. PMID: 38591430.
Dhakal, P, Sy, M, Sutamtewagul, G, Mou, E, Yu, N, Pemmaraju, N. Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting. Journal of Immunotherapy and Precision Oncology 7(3):205-209, 2024. e-Pub 2024. PMID: 39219995.
Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica 109(8):2660-2664, 2024. e-Pub 2024. PMID: 38572554.
Dhakal P, Sy M, Sutamtewagul G, Mou E, Yu N, Pemmaraju N. Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting. J Immunother Precis Oncol 7(3):205-209, 2024. e-Pub 2024. PMID: 39219995.
Urrutia, S, Bose, P, Alvarado, Y, Borthakur, G, Ravandi-Kashani, F, Daver, N, Pemmaraju, N, Jabbour, EJ, Takahashi, K, Kadia, TM, DiNardo, C, Kornblau, SM, Kanagal Shamanna, R, Huang, X, Bodden, K, Kantarjian, HM, Garcia-Manero, G. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML. Blood Neoplasia 1(2), 2024. e-Pub 2024.
Uryu H, Saeki K, Haeno H, Kapadia CD, Furudate K, Nangalia J, Chapman MS, Zhao L, Hsu JI, Zhao C, Chen S, Tanaka T, Li Z, Yang H, DiNardo C, Daver N, Pemmaraju N, Jain N, Ravandi F, Zhang J, Song X, Thompson E, Tang H, Little L, Gumbs C, Orlowski RZ, Qazilbash M, Bhalla K, Colla S, Kantarjian H, Shamanna RK, Ramos CB, Nakada D, Futreal PA, Shpall E, Goodell M, Garcia-Manero G, Takahashi K. Clonal evolution of hematopoietic stem cells after cancer chemotherapy. bioRxiv, 2024. e-Pub 2024. PMID: 38826462.
Abuasab T, Mohamed S, Pemmaraju N, Kadia TM, Daver N, DiNardo CD, Ravandi F, Qiao W, Montalban-Bravo G, Borthakur G. BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. Leuk Lymphoma:1-6. e-Pub 2024. PMID: 38696743.
Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38(5):1178-1181, 2024. e-Pub 2024. PMID: 38418609.
Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99(4):792-796, 2024. e-Pub 2024. PMID: 38361282.
Hu X, Ediriwickrema A, Saleem A, Tan B, Pemmaraju N, Mannis GN. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res 139:107479, 2024. e-Pub 2024. PMID: 38492495.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
Khan F, Hashmi F, Ghahramanyan N, Baloyan E, Tamamyan G, Konopleva M, Pemmaraju N, Voskanyan A. Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting. Oncology (Williston Park) 38(3):104-106, 2024. e-Pub 2024. PMID: 38517410.
Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, Sweet KL, Pemmaraju N, Lane AA, Torres-Miñana L, Thompson JE, Konopleva MY, Sloss CM, Watkins K, Bedse G, Du Y, Malcolm KE, Zweidler-McKay PA, Kantarjian HM. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol 25(3):388-399, 2024. e-Pub 2024. PMID: 38423051.
Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol 204(3):898-909, 2024. e-Pub 2024. PMID: 37946611.
Birdwell CE, Fiskus W, Kadia TM, Mill CP, Sasaki K, Daver N, DiNardo CD, Pemmaraju N, Borthakur G, Davis JA, Das K, Sharma S, Horrigan S, Ruan X, Su X, Khoury JD, Kantarjian H, Bhalla KN. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia 38(3):545-556, 2024. e-Pub 2024. PMID: 38086946.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv 8(4):909-915, 2024. e-Pub 2024. PMID: 38207208.
Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, Palmer J, Pettit K, Nath UK, Yacoub A, Molina A, Saks SR, Modi NB, Valone FH, Khanna S, Gupta S, Verstovsek S, Ginzburg YZ, Hoffman R, Investigators RT. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med 390(8):723-735, 2024. e-Pub 2024. PMID: 38381675.
Lane AA, Garcia JS, Raulston EG, Garzon JL, Galinsky I, Baxter EW, Leonard R, DeAngelo DJ, Luskin MR, Reilly CR, Stahl M, Stone RM, Vedula RS, Wadleigh MM, Winer ES, Mughal T, Brooks C, Gupta IV, Stevenson KE, Neuberg DS, Ren S, Keating J, Konopleva M, Stein A, Pemmaraju N. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv 8(3):591-602, 2024. e-Pub 2024. PMID: 38052038.
Pemmaraju N, Cuglievan B, Lasky J, Kheradpour A, Hijiya N, Stein AS, Meshinchi S, Mullen CA, Angelucci E, Vinti L, Mughal TI, Pawlowska AB. Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients. EJHaem 5(1):61-69, 2024. e-Pub 2024. PMID: 38406504.
Andanamala, H, Pemmaraju, N, Al-Juhaishi, T. Challenges and practical considerations in the management of blastic plasmacytoid dendritic cell neoplasm. Leukemia Research Reports 22, 2024. e-Pub 2024. PMID: 39563865.
Andanamala H, Pemmaraju N, Al-Juhaishi T. Challenges and practical considerations in the management of blastic plasmacytoid dendritic cell neoplasm: A single-center experience. Leuk Res Rep 22:100486, 2024. e-Pub 2024. PMID: 39563865.
Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, Rampal RK. Moving towards disease modification in polycythemia vera. Blood 142(22):1859-1870, 2023. e-Pub 2023. PMID: 37729609.
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
He J, Garcia MB, Connors JS, Nuñez CA, Quesada AE, Gibson A, Roth M, Cuglievan B, Pemmaraju N, McCall D. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm. J Pediatr Hematol Oncol 45(8):e1001-e1004, 2023. e-Pub 2023. PMID: 37661300.
Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce S, Estrov Z, Kantarjian H, Verstovsek S. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol 146(6):522-529, 2023. e-Pub 2023. PMID: 37699357.
Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol 98(11):1711-1720, 2023. e-Pub 2023. PMID: 37635400.
Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica 108(10):2626-2638, 2023. e-Pub 2023. PMID: 37078252.
Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood 142(12):1056-1070, 2023. e-Pub 2023. PMID: 37339579.
Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour EJ, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J 13(1):148, 2023. e-Pub 2023. PMID: 37735426.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. The role of therapy in the outcome of patients with myelofibrosis. Cancer 129(18):2828-2835, 2023. e-Pub 2023. PMID: 37243913.
Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica 108(9):2331-2342, 2023. e-Pub 2023. PMID: 36951163.
Sasaki K, Ravandi F, DiNardo C, Welch MA, Kadia T, Kantarjian H. Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2023. PMID: 37730483.
Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia 37(7):1444-1453, 2023. e-Pub 2023. PMID: 37138019.
Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
Haddad FG, Kantarjian HM, Bidikian A, Jabbour EJ, Short NJ, Ning J, Xiao L, Pemmaraju N, DiNardo CD, Kadia TM, Marx KR, Garcia-Manero G, Ravandi F, Sasaki K, Issa GC. Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer 129(12):1866-1872, 2023. e-Pub 2023. PMID: 36882573.
Pemmaraju N, Bose P, Rampal R, Gerds AT, Fleischman A, Verstovsek S. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma 64(6):1-19, 2023. e-Pub 2023. PMID: 37081809.
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2023. PMID: 36287248.
Beird H, Yin CC, Khoury JD, Pierce S, Abbas HA, Zhao L, Skwarska A, Qazilbash M, Konopleva M, Futreal PA, Pemmaraju N. TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv 7(10):2000-2003, 2023. e-Pub 2023. PMID: 36689729.
Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. e-Pub 2023. PMID: 37196217.
Harrold E, Latham A, Pemmaraju N, Lieu CH. Early-Onset GI Cancers: Rising Trends, Genetic Risks, Novel Strategies, and Special Considerations. Am Soc Clin Oncol Educ Book 43:e398068, 2023. e-Pub 2023. PMID: 37235819.
Babakhanlou R, Verstovsek S, Pemmaraju N, Rojas-Hernandez CM. Secondary erythrocytosis. Expert Rev Hematol 16(4):1-7, 2023. e-Pub 2023. PMID: 36927204.
Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2023. PMID: 36322818.
Verstovsek S, Pemmaraju N, Reaven NL, Funk SE, Woody T, Valone F, Gupta S. Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Ann Hematol 102(3):571-581, 2023. e-Pub 2023. PMID: 36637474.
Pagano L, Zinzani PL, Pileri S, Quaglino P, Cuglievan B, Berti E, Pemmaraju N, Onida F, Willemze R, Orfao A, Barosi G. Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel. Hemasphere 7(3):e841, 2023. e-Pub 2023. PMID: 36844178.
Boyiadzis M, Desai P, Daskalakis N, Donnellan W, Ferrante L, Goldberg JD, Grunwald MR, Guttke C, Li X, Perez-Simon JA, Salamero O, Tucker T, Xu X, Yang J, Pemmaraju N, Alonso-Dominguez JM. First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia. Clin Transl Sci 16(3):429-435, 2023. e-Pub 2023. PMID: 36564917.
Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol 98(3):E53-E56, 2023. e-Pub 2023. PMID: 36565294.
Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, Cai T, Su X, Skwarska A, Guerra V, Kuruvilla V, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Collins M, Sweeney S, Busquet J, Rathore A, Deng Q, Green M, Grant S, Demo S, Choudhary G, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett G, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Komblau S, Daver N, Naqvi K, Short N, Garcia-Manero G, Tiziani S, Verma A. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Res Sq, 2023. e-Pub 2023. PMID: 36865338.
Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. e-Pub 2023. PMID: 36458426.
Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver N, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. Blood 141(6):567-578, 2023. e-Pub 2023. PMID: 36399715.
Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia Across Therapy Subtypes. Am J Hematol 97(12):1599-1606, 2022. e-Pub 2022. PMID: 36117258.
Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):JCO2102823, 2022. e-Pub 2022. PMID: 35704787.
Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol 35(11):1677-1683, 2022. e-Pub 2022. PMID: 35690645.
Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour EJ, Takahashi K, Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol 97(11):1427-1434, 2022. e-Pub 2022. PMID: 36053747.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma 63(11):1-5, 2022. e-Pub 2022. PMID: 35787095.
Pemmaraju N, Harrison C, Gupta V, Verstovsek S, Scott B, Oh ST, Palandri F, Al-Ali HK, Sobas M, McMullin MF, Mesa R, Buckley S, Roman-Torres K, Vannucchi A, Yacoub A. Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis. EJHaem 3(4):1346-1351, 2022. e-Pub 2022. PMID: 36467816.
Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
Venugopal S, Borthakur G, Daver N, DiNardo CD, Pemmaraju N, Short NJ, Abbas HA, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv 6(19):5546-5549, 2022. e-Pub 2022. PMID: 35201293.
Venugopal S, Kantarjian H, Maiti A, Short NJ, Montalban-Bravo G, Alvarado Y, Chien K, Kanagal-Shamanna R, Pemmaraju N, Daver N, Kadia T, Borthakur G, Jabbour E, Garcia-Manero G. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Clin Lymphoma Myeloma Leuk 22 Suppl 2:S321, 2022. e-Pub 2022. PMID: 36163977.
Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien K, Pemmaraju N, Takahashi K, Short N, Daver N, Issa G, Jain N, Bull-Linderman D, DiNardo C, Montalban-Bravo G, Garcia-Manero G, Sasaki K, Ravandi F, Kadia T. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
Pemmaraju N, Cuglievan B, Lasky J, Kheradpour A, Hijiya N, Stein AS, Meshinchi S, Mullen C, Angelucci E, Vinti L, Mughal TI, Pawlowska A. AML-392 Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123-Targeted Therapy. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S244-S245, 2022. e-Pub 2022. PMID: 36163828.
Sasaki K, Jabbour E, Montalban-Bravo G, Darbaniyan F, Do KA, Class C, Short NJ, Kanagal-Shamana R, Kadia T, Borthakur G, Pemmaraju N, Cortes J, Ravandi F, Alvarado Y, Chien K, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Soltysiak K, Yang H, Kantarjian HM, Garcia-Manero G. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid 1(10):EVIDoa2200034, 2022. e-Pub 2022. PMID: 38319837.
Pemmaraju N, Kuykendall A, Kremyanskaya M, Ginzburg Y, Ritchie E, Gotlib J, Gerds A, Palmer J, Valone F, O'Connor P, Modi N, Gupta S, Hoffman R, Verstovsek S. MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S338-S339, 2022. e-Pub 2022. PMID: 36164011.
Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-355 Patients With Prefibrotic Myelofibrosis and Inferior Outcome, a Single-Center Analysis. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334-S335, 2022. e-Pub 2022. PMID: 36164004.
Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-354 Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334, 2022. e-Pub 2022. PMID: 36164003.
Chien K, Kim K, Li Z, Shamanna RK, Ong F, Bravo GM, Kadia T, Jabbour E, Pemmaraju N, Hammond D, Short N, Ravandi F, Alvarado Y, Pierce S, Dong XQ, Kantarjian H, Garcia-Manero G. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S311, 2022. e-Pub 2022. PMID: 36163957.
Pemmaraju N, Konopleva M, Sweet K, Stein A, Vasu S, Rizzieri D, Wang ES, Kantarjian H, Brooks C, Mughal T, Lane A. AML-465 Tagraxofusp, an Anti-CD123 Therapy, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm: Sub-Analysis of a Pivotal Trial by Age and Baseline Disease Involvement. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S254, 2022. e-Pub 2022. PMID: 36163847.
Kim K, Ong F, Li Z, Shamanna RK, Bravo GM, Kadia T, Jabbour E, Pemmaraju N, Hammond D, Short N, Ravandi F, Alvarado Y, Pierce S, Dong XQ, Kantarjian H, Garcia-Manero G, Chien K. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S313-S314, 2022. e-Pub 2022. PMID: 36163960.
Abuasab T, Senapati J, Kadia T, Ravandi F, DiNardo C, Pemmaraju N, Ohanion M, Alvarado Y, Kantarjian H, Borthakur G. AML-325 Prognostic Impact of RAS and C-KIT Mutations (Single vs. Multiple) in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated With a Fludarabine, Cytarabine, and G-CSF (FLAG)- Based Regimen. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S235-S236, 2022. e-Pub 2022. PMID: 36163808.
Ong F, Kim K, Shamanna RK, DiNardo C, Takahashi K, Kadia T, Jabbour E, Short NJ, Hammond D, Pemmaraju N, Pierce SA, Bravo GM, Kantarjian H, Garcia-Manero G, Chien KS. MDS-508 Contemporary Evaluation of a Cohort of Patients With Clonal Hematopoiesis (CH): A Single Institution Experience. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S319, 2022. e-Pub 2022. PMID: 36163972.
Haddad FG, Kantarjian H, Short NJ, Konopleva M, Jain N, Huang X, Ravandi F, Wierda W, Borthakur G, Sasaki K, Issa G, Alvarado Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S204, 2022. e-Pub 2022. PMID: 36163747.
Abuasab T, Alvarado Y, Issa G, Islam R, James N, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Pemmaraju N, Bravo GM, Pierce S, DiNardo C, Kadia T, Daver N, Konopleva M, Garcia-Manero G, Ravandi F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S237, 2022. e-Pub 2022. PMID: 36163813.
Abuasab T, Mohamed SF, Biostatistics HH, Biostatistics XW, Sasaki K, Yilmaz M, Kadia T, DiNardo C, Daver N, Pemmaraju N, Ravandi F, Kantarjian H, Garcia-Manero G, Takahashi K. AML-387 Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD). Clin Lymphoma Myeloma Leuk 22 Suppl 2:S243, 2022. e-Pub 2022. PMID: 36163827.
Pemmaraju N, Wilson NR, Senapati J, Economides MP, Guzman ML, Neelapu SS, Kazemimood R, Davis RE, Jain N, Khoury JD, Sugita M, Cai T, Smith J, Frattini MG, Garton A, Roboz G, Konopleva M. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res 121:106928, 2022. e-Pub 2022. PMID: 35963025.
Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol 40(26):JCO2200034, 2022. e-Pub 2022. PMID: 35820082.
Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed or Refractory AML Harboring RAS Pathway-Activating Mutations. Acta Haematol 145(5):529-536, 2022. e-Pub 2022. PMID: 35717939.
Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):1-10, 2022. e-Pub 2022. PMID: 35442137.
Wilson NR, Jain P, Gomez JA, Lu H, Pemmaraju N. Concurrent myelodysplasia and monoclonal B lymphocytosis in VEXAS syndrome. Leuk Res 120:106909, 2022. e-Pub 2022. PMID: 35820269.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
El Hussein S, Yabe M, Wang W, Pemmaraju N, Loghavi S, Jelloul FZ, Fang H, Medeiros LJ, Burack WR, Evans AG, Liesveld JL, Bennett JM. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms. EJHaem 3(3):954-957, 2022. e-Pub 2022. PMID: 36051075.
Kim K, Bazinet A, Loghavi S, Konopleva M, Bhalla K, Daver N, Khoury JD, Kadia T, Wilson NR, Curry JL, Heberton M, Miller D, Pierce S, Borthakur G, Pemmaraju N. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res 119:106884, 2022. e-Pub 2022. PMID: 35691130.
Wang W, Xu J, Khoury JD, Pemmaraju N, Fang H, Miranda RN, Yin CC, Hussein SE, Jia F, Tang Z, Hu S, Konopleva M, Medeiros LJ, Wang SA. Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 14(14), 2022. e-Pub 2022. PMID: 35884435.
Gerds AT, Yu J, Scherber RM, Paranagama D, Kish JK, Visaria J, Singhal M, Verstovsek S, Pemmaraju N. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes. Acta Haematol 145(4):1-5, 2022. e-Pub 2022. PMID: 35008087.
Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol 97(7):856-864, 2022. e-Pub 2022. PMID: 35357036.
Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent Cytoreduction for Newly Diagnosed AML patients Allows Acquisition of Pretreatment Genomic Data and Enrollment on Investigational Clinical Trials. Am J Hematol 97(7):885-894, 2022. e-Pub 2022. PMID: 35413152.
Pemmaraju N, Garcia JS, Potluri J, Harb JG, Sun Y, Jung P, Qin QQ, Tantravahi SK, Verstovsek S, Harrison C. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol 9(6):e434-e444, 2022. e-Pub 2022. PMID: 35576960.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Frontline HCVAD. Blood Adv 6(10):3027-3035, 2022. e-Pub 2022. PMID: 35061885.
Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol 40(15):JCO2102188, 2022. e-Pub 2022. PMID: 35180010.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
Khanlari M, Yin CC, Takahashi K, Lachowiez C, Tang G, Loghavi S, Bah I, Wang W, Konoplev S, Medeiros LJ, Pemmaraju N, Khoury JD, Wang SA. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia 36(5):1343-1350, 2022. e-Pub 2022. PMID: 35279700.
Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol 97(5):574-582, 2022. e-Pub 2022. PMID: 35150150.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. e-Pub 2022. PMID: 35483396.
Cai T, Gouble A, Black KL, Skwarska A, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Zhang Q, Galetto R, Filipe S, Cavazos A, Han L, Kuruvilla V, Ma H, Weng C, Liu CG, Liu X, Konoplev S, Gu J, Tang G, Su X, Al-Atrash G, Ciurea S, Neelapu SS, Lane AA, Kantarjian H, Guzman ML, Pemmaraju N, Smith J, Thomas-Tikhonenko A, Konopleva M. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun 13(1):2228, 2022. e-Pub 2022. PMID: 35484100.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer 128(8):1658-1665, 2022. e-Pub 2022. PMID: 35077575.
Pemmaraju N, Gerds AT, Yu J, Parasuraman S, Shah A, Xi A, Kumar S, Scherber RM, Verstovsek S. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leuk Res 115:106809, 2022. e-Pub 2022. PMID: 35220060.
Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved Outcomes Among Newly Diagnosed Patients with FLT3-ITD Mutated AML Treated with Contemporary Therapy: Revisiting the ELN Adverse Risk Classification. Am J Hematol 97(3):329-337, 2022. e-Pub 2022. PMID: 34981570.
Gangat N, Konopleva M, Patnaik MM, Jabbour E, DiNardo C, Al-Kali A, Foran JM, Granroth GL, Olteanu H, Kadia T, Tefferi A, Pemmaraju N. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol 97(2):E62-E67, 2022. e-Pub 2021. PMID: 34807470.
Togami K, Chung SS, Madan V, Booth CAG, Kenyon CM, Cabal-Hierro L, Taylor J, Kim SS, Griffin GK, Ghandi M, Li J, Li YY, Angelot-Delettre F, Biichle S, Seiler M, Buonamici S, Lovitch SB, Louissaint A, Morgan EA, Jardin F, Piccaluga PP, Weinstock DM, Hammerman PS, Yang H, Konopleva M, Pemmaraju N, Garnache-Ottou F, Abdel-Wahab O, Koeffler HP, Lane AA. Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discov 12(2):522-541, 2022. e-Pub 2021. PMID: 34615655.
Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2021. PMID: 34629467.
Wilson NR, Pemmaraju N. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opin Pharmacother:1-8. e-Pub 2022. PMID: 35060807.
Abla D, Abboud MR, Noun D, Tarek N, Pemmaraju N. Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review. Leuk Res Rep 17:100313, 2022. e-Pub 2022. PMID: 35462725.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
Abou Dalle I, Kantarjian H, Daver N, Masarova L, Pemmaraju N, Bose P, Garcia-Manero G, Verstovsek S. Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol 100(12):2957-2960, 2021. e-Pub 2021. PMID: 34350483.
Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer 127(22):4213-4220, 2021. e-Pub 2021. PMID: 34343352.
Tanaka T, Morita K, Wang F, Loghavi S, Furudate K, Sasaki Y, Little LD, Gumbs CE, Matthews J, Daver NG, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal A, Takahashi K. Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood 138(18):1733-1739, 2021. e-Pub 2021. PMID: 34115096.
Batta K, Bossenbroek HM, Pemmaraju N, Wilks DP, Chasty R, Dennis M, Milne P, Collin M, Beird HC, Taylor J, Patnaik MM, Cargo CA, Somervaille TCP, Wiseman DH. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia 35(11):3299-3303, 2021. e-Pub 2021. PMID: 33833384.
Yin CC, Pemmaraju N, You MJ, Li S, Xu J, Wang W, Tang Z, Alswailmi O, Bhalla KN, Qazilbash MH, Konopleva M, Khoury JD. Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34884997.
Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver N. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer 127(20):3761-3771, 2021. e-Pub 2021. PMID: 34171128.
Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver NG, Pierce SR, Jabbour EJ, Kadia TM, DiNardo CD, Garcia-Manero G, Qazilbash MH, Konopleva MY, Kantarjian HM. Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood 138(15):1373-1377, 2021. e-Pub 2021. PMID: 34098573.
Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer 127(19):3541-3551, 2021. e-Pub 2021. PMID: 34182597.
DiPippo AJ, Wilson NR, Pemmaraju N. Targeting CD123 in BPDCN: an emerging field. Expert Rev Hematol:1-12. e-Pub 2021. PMID: 34607517.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):JCO2003736, 2021. e-Pub 2021. PMID: 34043428.
Brown SA, Yang EH, Reza N, Guha A, Ismail-Khan R, Pemmaraju N, Fradley MG, Lopez-Mattei J. #JACCCardioOnc: Evolution of a Dedicated Social Media Strategy for JACC: CardioOncology. JACC CardioOncol 3(3):461-464, 2021. e-Pub 2021. PMID: 34604810.
Pemmaraju N. A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic. Cancer 127(16):2867-2869, 2021. e-Pub 2021. PMID: 33891316.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia. Am J Hematol 96(8):1000-1007, 2021. e-Pub 2021. PMID: 33991360.
Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 96(8):914-924, 2021. e-Pub 2021. PMID: 33901324.
Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma:1-9. e-Pub 2021. PMID: 34380367.
Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552-e561, 2021. e-Pub 2021. PMID: 34329576.
Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. e-Pub 2021. PMID: 34424319.
Pemmaraju N. Rare Blood Cancers in 2021: Importance of Continued Exchange of Ideas. J Immunother Precis Oncol 4(3):115-116, 2021. e-Pub 2021. PMID: 35663105.
Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol 96(7):E246-E249, 2021. e-Pub 2021. PMID: 33811786.
El Hussein S, Wang W, Wang SA, Loghavi S, Wang X, Qiu L, Fang H, Medeiros LJ, Aung P, Torres Cabala C, Jorgensen JL, Pemmaraju N, Khoury JD. Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. Leuk Lymphoma:1-4. e-Pub 2021. PMID: 34304666.
Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer 127(11):1894-1900, 2021. e-Pub 2021. PMID: 33449377.
Shah MV, Saliba RM, Verma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Zeev E, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis 72(10):1755-1763, 2021. e-Pub 2020. PMID: 32236406.
Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35(5):1494-1499, 2021. e-Pub 2021. PMID: 33846541.
Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk 21(5):318-327.e6, 2021. e-Pub 2021. PMID: 33551345.
Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021. PMID: 33597098.
Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
Patnaik MM, Mughal TI, Brooks C, Lindsay R, Pemmaraju N. Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy. Leuk Lymphoma:1-19. e-Pub 2021. PMID: 33999767.
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID, Working Group CCT. Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol 18(5):320, 2021. e-Pub 2021. PMID: 33758378.
Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. e-Pub 2021. PMID: 33885753.
Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer 127(8):1246-1259, 2021. e-Pub 2021. PMID: 33270904.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
Wang W, Khoury JD, Miranda RN, Jorgensen JL, Xu J, Loghavi S, Li S, Pemmaraju N, Nguyen T, Medeiros LJ, Wang SA. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica 106(4):1047-1055, 2021. e-Pub 2021. PMID: 32241840.
Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma 62(4):1-14, 2021. e-Pub 2021. PMID: 33283580.
Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J 11(3):60, 2021. e-Pub 2021. PMID: 33731681.
Pemmaraju N. Targeting the p-D-C: easy as C-D-1-2-3?. Blood 137(10):1277-1278, 2021. e-Pub 2021. PMID: 33704391.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
Chen NC, Borthakur G, Pemmaraju N. Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms. Leuk Lymphoma 62(3):1-10, 2021. e-Pub 2021. PMID: 33161793.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 34238762.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 33681815.
Pemmaraju N, Wilson NR, Clementi Doan T, Qiao W, Peterson SK, Zoeller V, Schorr A, Verstovsek S. Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era. Leuk Lymphoma:1-8, 2021. e-Pub 2021. PMID: 33749512.
Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 35(3):691-700, 2021. e-Pub 2021. PMID: 32561839.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol 96(2):E50-E53, 2021. e-Pub 2021. PMID: 33156969.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2021. PMID: 33119202.
Wilson NR, Fang H, Loghavi S, Wang W, Tang G, Haltom RO, Rausch CR, McClain KL, Rao KV, Popat UR, Fayad LE, Champa N, Calvo KR, Allen CE, Kadia TM, Pemmaraju N. Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. Br J Haematol 192(3):667-671, 2021. e-Pub 2021. PMID: 33238033.
Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol 95(11):E313-E315, 2020. e-Pub 2020. PMID: 32804409.
Jammal N, Rausch CR, Kadia TM, Pemmaraju N. Cell Cycle Inhibitors for the Treatment of Acute Myeloid Leukemia: A Review of Phase 2 & 3 Clinical Trials. Expert Opin Emerg Drugs:1-9. e-Pub 2020. PMID: 33161749.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3). Am J Hematol. e-Pub 2020. PMID: 32886803.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. e-Pub 2020. PMID: 32896301.
Cherng HJ, Jain N, Thakral B, Muzzafar T, Miranda RN, Tan D, Rashid A, Kalhor N, Hahn AW, Byers LA, Parseghian CM, Ferrajoli A, Pemmaraju N. Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leuk Res 98:106445. e-Pub 2020. PMID: 32937250.
Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, Ferrero S, Sato Y, Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F, working group CDCNSABDCI, working group TGI. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol. e-Pub 2020. PMID: 32894785.
Aung PP, Pemmaraju N, Torres-Cabala CA, Duvic M, Konopleva M, Khoury JD, Prieto VG. Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall. J Dermatol. e-Pub 2020. PMID: 32770556.
Pemmaraju N, Konopleva M. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Adv 4(16):4020-4027, 2020. e-Pub 2020. PMID: 32841341.
Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma:1-8. e-Pub 2020. PMID: 32755333.
Pandey RK, DiPippo A, Kadia T, Pemmaraju N, Workeneh BT, Jabbour E, Ravandi F, Jain N. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leuk Lymphoma:1-3. e-Pub 2020. PMID: 32654562.
Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver N, Ravandi F, Pemmaraju N. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol. e-Pub 2020. PMID: 32686139.
Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. e-Pub 2020. PMID: 32589978.
Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia. Am J Hematol. e-Pub 2020. PMID: 32681739.
Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. e-Pub 2020. PMID: 32697338.
Alotaibi AS, Abdulrazzaq M, Patel KP, Ravandi F, Konoplev S, Bueso-Ramos C, Yin CC, Muzzafar T, Tang G, Futreal A, Jain N, Konopleva MY, Pemmaraju N. Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant. Leuk Lymphoma:1-3. e-Pub 2020. PMID: 32657180.
Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. e-Pub 2020. PMID: 32546726.
Mughal TI, Pemmaraju N, Psaila B, Radich J, Bose P, Lion T, Kiladjian JJ, Rampal R, Jain T, Verstovsek S, Yacoub A, Cortes JE, Mesa R, Saglio G, Van Etten RA. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol. e-Pub 2020. PMID: 32592408.
Lee SS, McCue D, Pemmaraju N. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. Expert Rev Anticancer Ther. e-Pub 2020. PMID: 32460559.
Navada SC, Garcia-Manero G, OdchimarReissig R, Pemmaraju N, Alvarado Y, Ohanian MN, John RB, Demakos EP, Zbyszewski PS, Maniar M, Woodman RC, Fruchtman SM, Silverman LR. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leuk Res 94:106369. e-Pub 2020. PMID: 32442785.
Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J 10(5):48, 2020. e-Pub 2020. PMID: 32366841.
Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. e-Pub 2020. PMID: 32251497.
Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel K, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. e-Pub 2020. PMID: 32356320.
Garcia-Manero G, Pemmaraju N, Alvarado Y, Naqvi K, Ravandi F, Jabbour E, De Lumpa R, Kantarjian H, Advani A, Mukherjee S, Gerds A, Carraway HE, Nazha A, Iwamura H, Murase M, Bavisotto L, Kurman M, Maier G, Johansen M, Sekeres MA. Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leuk Lymphoma:1-11. e-Pub 2020. PMID: 32264726.
Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv 4(8):1690-1699, 2020. e-Pub 2020. PMID: 32330243.
Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. e-Pub 2020. PMID: 32099037.
Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482–495, 2020. e-Pub 2020.
Daver N, Price A, Benton CB, Patel K, Zhang W, Konopleva M, Pemmaraju N, Takahashi K, Andreeff M, Borthakur G. First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations. Front Oncol 10:1538, 2020. e-Pub 2020. PMID: 32984009.
Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, Daver N. Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. Front Oncol 10:588876, 2020. e-Pub 2020. PMID: 33194747.
Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2020. PMID: 33585199.
Alfayez M, Konopleva M, Pemmaraju N. Role of Tagraxofusp in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Expert Opin Biol Ther. e-Pub 2019. PMID: 31801379.
Beird HC, Khan M, Wang F, Alfayez M, Cai T, Zhao L, Khoury J, Futreal PA, Konopleva M, Pemmaraju N. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood Cancer J 9(12):99, 2019. e-Pub 2019. PMID: 31811114.
Alfayez M, Richard-Carpentier G, Jabbour E, Vishnu P, Naqvi K, Sasaki K, Cortes J, Pemmaraju N. Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. Br J Haematol 187(4):543-545, 2019. e-Pub 2019. PMID: 31584727.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. e-Pub 2019. PMID: 31724006.
Ye MT, Wang Y, Wang SA, Pemmaraju N, Daver N, Verstovsek S, Zhang Y, Zuo Z, Medeiros LJ, You MJ. Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leuk Lymphoma:1-4. e-Pub 2019. PMID: 31750750.
Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, Pemmaraju N, Wierda W, Kadia T. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma:1-5. e-Pub 2019. PMID: 31566032.
Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. e-Pub 2019. PMID: 31553487.
Economides MP, McCue D, Lane AA, Pemmaraju N. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert Rev Clin Pharmacol. e-Pub 2019. PMID: 31465247.
Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. e-Pub 2019. PMID: 31310323.
Alfayez M, Burger JA, Kadia T, Xu TH, Szvalb AD, Pemmaraju N. Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia. Leuk Lymphoma:1-2. e-Pub 2019. PMID: 31305193.
Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. e-Pub 2019. PMID: 31296578.
Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, Ortega V, Lyapichev K, Nagarajan P, Alfattal R, Angelova E, Tang Z, Loghavi S, Kanagal-Shamanna R, Miranda RN, Pemmaraju N, Bhalla K, Konopleva M, Medeiros LJ, Khoury JD. Dual Expression of TCF4 and CD123 is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. Am J Surg Pathol. e-Pub 2019. PMID: 31261288.
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. e-Pub 2019. PMID: 31237017.
Economides MP, McCue D, Borthakur G, Pemmaraju N. Topoisomerase II inhibitors in AML: past, present, and future. Expert Opin Pharmacother:1-8. e-Pub 2019. PMID: 31136213.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA, Yin CC, Konopleva M, Zheng X, Wang J, Tang Z, Medeiros LJ, Prieto VG, Pemmaraju N, Khoury JD. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31109153.
Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. e-Pub 2019. PMID: 30985931.
Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA. Emerging translational science discoveries, clonal approaches and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol. e-Pub 2019. PMID: 31013548.
Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med 380(17):1628-1637, 2019. e-Pub 2019. PMID: 31018069.
Tallis E, Loghavi S, Jorgensen JL, Wang S, Khoury JD, Bueso-Ramos CB, Jain N, Borthakur G, Pemmaraju N. Patient with mixed-phenotype acute leukemia with CBFB rearrangement. Leuk Lymphoma:1-3. e-Pub 2019. PMID: 31012358.
Pemmaraju N. Treatment advances in blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol 17(4):207-209, 2019. e-Pub 2019. PMID: 31188810.
Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol. e-Pub 2019. PMID: 31005650.
Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. e-Pub 2019. PMID: 30796023.
Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. e-Pub 2019. PMID: 30811597.
Pemmaraju N, Konopleva M, Lane AA. More on Blastic Plasmacytoid Dendritic-Cell Neoplasms. N Engl J Med 380(7):695-6, 2019. e-Pub 2019. PMID: 30785714.
Swaminathan M, Borthakur G, Kadia TM, Ferrajoli A, Alvarado Y, Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DiNardo CD. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma:1-7. e-Pub 2019. PMID: 30773968.
Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. Blood Cancer J 9(2):7, 2019. e-Pub 2019. PMID: 30651532.
Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J 9(2):4, 2019. e-Pub 2019. PMID: 30647404.
Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol 12(1):1, 2019. e-Pub 2019. PMID: 30606227.
Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma:1-8. e-Pub 2019. PMID: 30632841.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2019. PMID: 30545576.
Alfayez M, Ivan D, Pemmaraju N, Daver N, DiNardo CD. Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 30957058.
Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5(12):e618-e627, 2018. e-Pub 2018. PMID: 30501869.
Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol. e-Pub 2018. PMID: 30467242.
Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S. The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol 97(11):2071-2080, 2018. e-Pub 2018. PMID: 29951914.
Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia TM, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discov. e-Pub 2018. PMID: 30409776.
Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res 73:21-23, 2018. e-Pub 2018. PMID: 30189324.
Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5(9):e411-e421, 2018. e-Pub 2018. PMID: 30115541.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood. e-Pub 2018. PMID: 30185431.
van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. e-Pub 2018. PMID: 30181172.
Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv 2(15):1807-1816, 2018. e-Pub 2018. PMID: 30054307.
Abaza Y, Cortes J, Ravandi F, Kadia T, Garcia-Manero G, Pemmaraju N, Shetty A, Pierce S, Qiao W, Kantarjian HM, Borthakur G. Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol. e-Pub 2018. PMID: 30074261.
Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. e-Pub 2018. PMID: 29723397.
Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol:JCO2017776757. e-Pub 2018. PMID: 29702001.
Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. e-Pub 2018. PMID: 29660836.
Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. e-Pub 2018. PMID: 29557496.
Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol. e-Pub 2018. PMID: 29550383.
Rausch CR, Paul S, Marx KR, Jabbour E, Pemmaraju N, Ferrajoli A, Kantarjian H. L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia. Clin Lymphoma Myeloma Leuk. e-Pub 2018. PMID: 29550108.
Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget 9(11):9714-9727, 2018. e-Pub 2018. PMID: 29515765.
Boddu PC, Wang SA, Pemmaraju N, Tang Z, Hu S, Li S, Xu J, Medeiros LJ, Tang G. 8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. Leuk Res 66:73-78. e-Pub 2018. PMID: 29407586.
Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. e-Pub 2018. PMID: 29352703.
Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol 140(1):30-39, 2018. e-Pub 2018. PMID: 30071517.
Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, Kadia T, Jorgensen J, Andreeff M, Hu S, Benton CB. Early detection of transformation to BPDCN in a patient with MDS. Exp Hematol Oncol 7:26, 2018. e-Pub 2018. PMID: 30323983.
DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical Experience with the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies. Am J Hematol. e-Pub 2017. PMID: 29218851.
Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol. e-Pub 2017. PMID: 29226426.
Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. e-Pub 2017. PMID: 29143068.
Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A Phase II Trial of Ruxolitinib in Combination with Azacytidine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms. Am J Hematol. e-Pub 2017. PMID: 29134664.
Abaza Y, Kantarjian HM, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, Khoury JD, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Am J Hematol. e-Pub 2017. PMID: 29047158.
Pemmaraju N. Editorial overview: Emerging importance of social media for real-time communication in the modern medical era. Semin Hematol 54(4):175-176, 2017. e-Pub 2017. PMID: 29153076.
Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. e-Pub 2017. PMID: 29027261.
Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia. e-Pub 2017. PMID: 28919634.
Tsai HJ, Jiang SS, Hung WC, Borthakur G, Lin SF, Pemmaraju N, Jabbour E, Bomalaski JS, Chen YP, Hsiao HH, Wang MC, Kuo CY, Chang H, Yeh SP, Cortes J, Chen LT, Chen TY. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. Sci Rep 7(1):11253, 2017. e-Pub 2017. PMID: 28900115.
Pemmaraju N, Rytting ME. Questions on asparaginase-associated pancreatitis. Lancet Oncol 18(9):1148-1149, 2017. e-Pub 2017. PMID: 28884687.
Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN. Blood. e-Pub 2017. PMID: 28774880.
Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Jabbour E, Borthakur G, Daver N, Pemmaraju N, Pierce S, Cortes J, Kadia TM. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma:1-4. e-Pub 2017. PMID: 28838278.
Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience. Am J Hematol. e-Pub 2017. PMID: 28850699.
Boddu P, Schlette E, Thakral B, Tang G, Pemmaraju N, Kadia T, Ferrajoli A, Ravandi F, Wierda W, Jain N. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. Hematol Oncol Stem Cell Ther. e-Pub 2017. PMID: 28830803.
Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Concurrent diagnosis of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica. e-Pub 2017. PMID: 28860345.
Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(7):1659, 2017. e-Pub 2017. PMID: 28338082.
Boddu P, Takahashi K, Pemmaraju N, Daver N, Benton CB, Pierce S, Konopleva M, Ravandi F, Cortes J, Kantarjian H, DiNardo CD. Influence of IDH on FLT3ITD status in newly diagnosed AML. Leukemia. e-Pub 2017. PMID: 28751773.
Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol 92(7):674-682, 2017. e-Pub 2017. PMID: 28370157.
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma:1-8. e-Pub 2017. PMID: 28718728.
Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. e-Pub 2017. PMID: 28708931.
Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. Haematologica. e-Pub 2017. PMID: 28729302.
Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110-116. e-Pub 2017. PMID: 28601551.
Ragon BK, Daver N, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal Residual Disease Eradication with Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia. Am J Hematol. e-Pub 2017. PMID: 28494506.
Pemmaraju N, Thompson MA, Mesa RA, Desai T. Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends. J Oncol Pract:JOP2017021634. e-Pub 2017. PMID: 28514195.
Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. e-Pub 2017. PMID: 28387922.
Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. e-Pub 2017. PMID: 28370097.
Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res 57:85-88. e-Pub 2017. PMID: 28324773.
Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, O'Brien S, Wang X, Huang X, Wang SA, Konopleva M, Konoplev S, Kadia T, Garris R, Pierce S, Garcia-Manero G, Cortes J, Ravandi F. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. e-Pub 2017. PMID: 28052371.
Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Novel BET protein proteolysis targeting chimera (BET-PROTAC) exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Leukemia. e-Pub 2017. PMID: 28042144.
Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA. Blastic Plasmacytoid Dendritic Cell Neoplasm is Dependent on BCL-2 and Sensitive to Venetoclax. Cancer Discov. e-Pub 2016. PMID: 27986708.
Ohanian M, Pemmaraju N, Rozovski U, Alattar ML, Estrov Z, Kundra V, Tung C, Ravandi F, Manning J, Abruzzo LV. Ocular extramedullary myeloid leukaemia. Br J Haematol. e-Pub 2016. PMID: 27879987.
Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia. Am J Hematol. e-Pub 2016. PMID: 27874212.
Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. e-Pub 2016. PMID: 27741352.
Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. e-Pub 2016. PMID: 27795561.
Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. Am J Hematol. e-Pub 2016. PMID: 27673440.
Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. e-Pub 2016. PMID: 27677740.
Pemmaraju N, Jain P, Medeiros LJ, Jorgenson JL, Jain N, Willis J, Kontoyiannis DP, Estrov Z, Wierda W. PET-positive lymphadenopathy in CLL - Not always Richter transformation. Am J Hematol. e-Pub 2016. PMID: 27677095.
Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma:1-6. e-Pub 2016. PMID: 27494751.
Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. e-Pub 2016. PMID: 27479888.
Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. e-Pub 2016. PMID: 27509035.
Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clin Case Rep 4(8):765-7, 2016. e-Pub 2016. PMID: 27525080.
Jain P, Nagarajan P, Prayag P, Benton CB, Kadia T, Groisberg R, Kontoyiannis DP, Mulanovich VE, Pemmaraju N. Mixed angioinvasive Exserohilum and Scedosporium infection in a patient with AML. Am J Hematol. e-Pub 2016. PMID: 27341684.
Vitale C, Jabbour E, Lu X, Yabe M, Shamanna RK, Daver N, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. Am J Hematol 91(4):E274-6, 2016. e-Pub 2016. PMID: 26798971.
Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented berlin-frankfurt-münster (ABFM), in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL), and comparison to the hyper-CVAD regimen. Am J Hematol. e-Pub 2016. PMID: 27178680.
Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer. e-Pub 2016. PMID: 27142181.
Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol 14(4):220-222, 2016. e-Pub 2016. PMID: 27166602.
Pemmaraju N, Kantarjian H, Ravandi F, Nogueras-Gonzalez GM, Huang X, O'Brien S, Wierda W, Garcia-Manero G, Thomas D, Pierce S, Verstovsek S, Borthakur G, Cortes J. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk 16(4):213-222.e2, 2016. e-Pub 2016. PMID: 26838606.
Jain P, Tang G, Konoplev SN, Kanagal-Shamanna R, Wang SA, Pemmaraju N, Daver N, Estrov Z. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. Am J Hematol 91(3):354-5, 2016. e-Pub 2016. PMID: 26437693.
Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver N, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk 16(3):152-62, 2016. e-Pub 2016. PMID: 26796981.
Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Shamanna RK, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 127(10):1269-75, 2016. e-Pub 2016. PMID: 26729897.
Perales MA, Drake EK, Pemmaraju N, Wood WA. Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer. Curr Hematol Malig Rep. e-Pub 2016. PMID: 26893061.
Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 30(2):268-73, 2016. e-Pub 2016. PMID: 26365212.
Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant 22(1):47-53, 2016. e-Pub 2016. PMID: 26343946.
Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer 122(2):238-48, 2016. e-Pub 2016. PMID: 26479889.
Jain P, Tang G, Huh YO, Yin CC, Zuo Z, Pemmaraju N, Estrov Z, Daver N. Philadelphia - positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation. Am J Hematol. e-Pub 2016. PMID: 26799924.
Pemmaraju N. The Sacred Trust. Am J Kidney Dis 66(6):A17-9, 2015. e-Pub 2015. PMID: 26593318.
Jain P, Verstovsek S, Wang W, Loghavi S, Torres HA, Estrov Z, Patel KP, Pemmaraju N. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leuk Lymphoma:1-5. e-Pub 2015. PMID: 26700872.
Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social Media and Myeloproliferative Neoplasms (MPN)-Focus on Twitter and the Development of a Disease-specific Community: #MPNSM. Curr Hematol Malig Rep 10(4):413-20, 2015. e-Pub 2015. PMID: 26411990.
Pemmaraju N, Mesa R. Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs). Hematology Am Soc Hematol Educ Program 2015(1):649-51, 2015. e-Pub 2015. PMID: 26637784.
Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. e-Pub 2015. PMID: 26432046.
Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol 2(9):e376-e383, 2015. e-Pub 2015. PMID: 26436130.
Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. Am J Hematol 90(8):752-3, 2015. e-Pub 2015. PMID: 25850565.
Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol 170(4):590-3, 2015. e-Pub 2015. PMID: 25716073.
Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 100(7):927-34, 2015. e-Pub 2015. PMID: 25682597.
Gowin K, Verstovsek S, Daver N, Pemmaraju N, Valdez R, Kosiorek H, Dueck A, Mesa R. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. Leuk Res 39(7):684-8, 2015. e-Pub 2015. PMID: 25922307.
Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(6):358-63, 2015. e-Pub 2015. PMID: 25630528.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver N, Verstovsek S. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. e-Pub 2015. PMID: 26183878.
Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. Haematologica. e-Pub 2015. PMID: 26088933.
Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood 125(21):3360-3363, 2015. e-Pub 2015. PMID: 25999449.
Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186-93, 2015. e-Pub 2015. PMID: 26688093.
Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(3):171-6, 2015. e-Pub 2015. PMID: 25441108.
Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, Fayad L, Pemmaraju N. Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis -TAFRO syndrome. Am J Hematol. e-Pub 2015. PMID: 25808231.
Pemmaraju N, Chang E. Healing words. CMAJ. e-Pub 2015. PMID: 25733740.
Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol 168(5):646-53, 2015. e-Pub 2015. PMID: 25312977.
Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(2):110-4, 2015. e-Pub 2015. PMID: 25107338.
Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II Study of Methotrexate, Vincristine, Pegylated-Asparaginase, and Dexamethasone (MOpAD) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Am J Hematol 90(2):120-4, 2015. e-Pub 2015. PMID: 25368968.
DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol 2(1):e12-20, 2015. e-Pub 2015. PMID: 26687423.
DiNardo CD, Tang G, Pemmaraju N, Wang SA, Pike A, Garcia-Manero G, Cortes J, Bueso-Ramos C, Kantarjian HM. Acute Myeloid Leukemia With t(10;11): A Pathological Entity With Distinct Clinical Presentation. Clin Lymphoma Myeloma Leuk 15(1):47-51, 2015. e-Pub 2015. PMID: 25081372.
Yin CC, Jain N, Mehrotra M, Zhagn J, Protopopov A, Zuo Z, Pemmaraju N, DiNardo C, Hirsch-Ginsberg C, Wang SA, Medeiros LJ, Chin L, Patel KP, Ravandi F, Futreal A, Bueso-Ramos CE. Identification of a Novel Fusion Gene, IRF2BP2-RARA, in Acute Promyelocytic Leukemia. J Natl Compr Canc Netw 13(1):19-22, 2015. e-Pub 2015. PMID: 25583766.
Pemmaraju N, Kantarjian H, Garcia-Manero G, Pierce S, Cardenas-Turanzas M, Cortes J, Ravandi F. Improving Outcomes for Patients with Acute Myeloid Leukemia in First Relapse: A Single Center Experience. Am J Hematol 90(1):27-30, 2015. e-Pub 2015. PMID: 25251041.
Pemmaraju N, Gill J, Krause JR. Hairy cell leukemia presenting with a lytic bone lesion. Proc (Bayl Univ Med Cent) 28(1):65-6, 2015. e-Pub 2015. PMID: 25552803.
Pemmaraju N, Sasaki K, Johnson D, Daver N, Afshar-Kharghan V, Chen M, Ahmed S, Colen RR, Kwon M, Huh Y, Borthakur G. Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. Front Oncol 5:29, 2015. e-Pub 2015. PMID: 25717439.
Shelburne SA, Ajami NJ, Chibucos MC, Beird HC, Tarrand J, Galloway-Peña J, Albert N, Chemaly RF, Ghantoji SS, Marsh L, Pemmaraju N, Andreeff M, Shpall EJ, Wargo JA, Rezvani K, Alousi A, Bruno VM, Futreal PA, Petrosino JF, Kontoyiannis DP. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS One 10(11):e0139851, 2015. e-Pub 2015. PMID: 26556047.
Pemmaraju N, Moliterno AR. From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management. Am Soc Clin Oncol Educ Book 35:139-45, 2015. e-Pub 2015. PMID: 25993152.
Pemmaraju N, Shetty AV, Prieto VG, Jain N, Kontoyiannis DP, Borthakur G. Disseminated Saprochaete capitata (formerly known as Geotrichum capitatum and Blastoschizomyces capitatus) in a patient with acute myeloid leukemia. Eur J Haematol 93(6):543-4, 2014. e-Pub 2014. PMID: 24592915.
Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer 120(23):3660-8, 2014. e-Pub 2014. PMID: 25042398.
Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res 38(10):1212-6, 2014. e-Pub 2014. PMID: 25217891.
Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 38(9):1126-9, 2014. e-Pub 2014. PMID: 25047979.
DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2, and DNMT3A mutations with outcome in older patients with AML treated with hypomethylating agents. Leuk Lymphoma 55(8):1925-9, 2014. e-Pub 2014. PMID: 24138309.
Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O'Brien S, Daver N. Extramedullary B Lymphoblastic Leukemia/Lymphoma (B-ALL/B-LBL): A Diagnostic Challenge. Clin Lymphoma Myeloma Leuk 14(4):e115-8, 2014. e-Pub 2014. PMID: 24589157.
Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to the interleukin-3 receptor, in patients with blastic plasmacytoid dendritic cell neoplasm. Blood 124(3):385-92, 2014. e-Pub 2014. PMID: 24859366.
Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs 23(7):943-54, 2014. e-Pub 2014. PMID: 24749672.
Jain P, Pemmaraju N, Ravandi F. Update on the Biology and Treatment Options for Hairy Cell Leukemia. Curr Treat Options Oncol 15(2):187-209, 2014. e-Pub 2014. PMID: 24652320.
Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated Nucleophosmin-1 (NPM1) in patients with Acute Myeloid Leukemia (AML) in remission and relapse. Leuk Lymphoma 55(6):1337-44, 2014. e-Pub 2014. PMID: 24004182.
Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics. Clin Lymphoma Myeloma Leuk 14(2):163-71, 2014. e-Pub 2014. PMID: 24461514.
Pemmaraju N, Gill J, Gupta S, Krause JR. Triple-hit lymphoma. Proc (Bayl Univ Med Cent) 27(2):125-7, 2014. e-Pub 2014. PMID: 24688198.
Jain P, Baez-Vallecillo L, Huh YO, Benjamini O, Abruzzo L, O'Brien S, Pemmaraju N, Keating M, Gagel RF, Estrov Z. Atypical chronic lymphocytic leukemia (CLL) with polyglandular autoimmune endocrinopathy (PGA) type II - a complex profile. Leuk Lymphoma 55(4):944-6, 2014. e-Pub 2014. PMID: 23829280.
DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia 28(4):958-61, 2014. e-Pub 2014. PMID: 24492324.
Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of Hyper-CVAD plus nelarabine as frontline therapy in adult T cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (LL)-MD Anderson cancer center experience. Leukemia 28(4):973-5, 2014. e-Pub 2014. PMID: 24157581.
Pemmaraju N, Chang E, Daver N, Patel K, Jorgensen J, Sabloff B, Verstovsek S, Borthakur G. Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature. Front Oncol 4:130, 2014. e-Pub 2014. PMID: 24918086.
Sasaki K, Pemmaraju N, Westin JR, Wang WL, Khoury JD, Podoloff DA, Moon B, Daver N, Borthakur G. A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine. Front Oncol 4:297, 2014. e-Pub 2014. PMID: 25401088.
Pemmaraju N, Cortes J. Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature. Acta Haematol 132(3-4):298-306, 2014. e-Pub 2014. PMID: 25228555.
Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JD. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 88(12):1055-61, 2013. e-Pub 2013. PMID: 23940084.
Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia (AML). Am J Hematol 88(11):961-6, 2013. e-Pub 2013. PMID: 23877926.
Jain N, Khoury JD, Pemmaraju N, Kollipara P, Kantarjian H, Verstovsek S. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. Blood 122(19):3387-8, 2013. e-Pub 2013. PMID: 24203930.
Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 122(16):2807-11, 2013. e-Pub 2013. PMID: 23896412.
Jain P, Lin P, Bueso-Ramos C, Verstovsek S, Pemmaraju N. Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS. Eur J Haematol 91(4):378-9, 2013. e-Pub 2013. PMID: 23772772.
Strati P, Daver N, Ravandi F, Pemmaraju NN, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S276-81, 2013. e-Pub 2013. PMID: 23969309.
Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy. Clin Lymphoma Myeloma Leuk 13(4):435-40, 2013. e-Pub 2013. PMID: 23763915.
Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MH. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 13(4):485-92, 2013. e-Pub 2013. PMID: 23769669.
Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, Estrov Z. Is acute myeloid leukemia a liquid tumor?. Int J Cancer 133(3):534-43, 2013. e-Pub 2013. PMID: 23280377.
Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol 161(5):659-66, 2013. e-Pub 2013. PMID: 23530930.
Ohanian M, Borthakur G, Quintas-Cardama A, Mathisen M, Cortés JE, Estrov Z, Pemmaraju N. Ocular Granulocytic Sarcoma: A Case Report and Literature Review of Ocular Extramedullary Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13(1):93-6, 2013. e-Pub 2013. PMID: 23017332.
Feng S, Liang X, Cruz MA, Vu H, Zhou Z, Pemmaraju N, Dong JF, Kroll MH, Afshar-Kharghan V. The interaction between factor H and Von Willebrand factor. PLoS One 8(8):e73715, 2013. e-Pub 2013. PMID: 23991205.
Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97(7):1029-35, 2012. e-Pub 2012. PMID: 22271898.
Pemmaraju N, Hamilton JP, Cameron AM, Sisson S, Moliterno AR. Abdominal venous thrombosis presenting in Myeloproliferative neoplasm with JAK2 V617F mutation: a case report. J Med Case Rep 6(1):102, 2012. e-Pub 2012. PMID: 22480324.
Pemmaraju N, Kantarjian H, Ravandi F, Cortes J. FLT3 inhibitors in the treatment of acute myeloid leukemia: The start of an era?. Cancer 117(15):3293-304, 2011. e-Pub 2011. PMID: 21319142.
Stein BL, Williams DM, Wang NY, Rogers O, Isaacs MA, Pemmaraju N, Spivak JL, Moliterno AR. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 95(7):1090-7, 2010. e-Pub 2010. PMID: 20133898.
Pemmaraju N, Feldman LS. Solifenacin-induced small bowel pseudo-obstruction. J Hosp Med 3(2):176-8, 2008. e-Pub 2008. PMID: 18438799.
Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia 21(10):2210-2, 2007. e-Pub 2007. PMID: 17507997.
Pemmaraju N, Dassopoulos T, Moliterno AR. An absorbing problem. Am J Med 120(3):229-30, 2007. e-Pub 2007. PMID: 17349442.

Review Articles

Haddad FG, Croden J, Sasaki K, Issa GC, Pemmaraju N, Kantarjian H, Jabbour E. Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm. Clin Lymphoma Myeloma Leuk, 2025. e-Pub 2025. PMID: 40883153.
Kuhn MWM, Pemmaraju N, Heidel FH. The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms. Leukemia 39(8):1824-1837, 2025. e-Pub 2025. PMID: 40374809.
Masarova L, Mascarenhas J, Rampal R, Hu W, Livingston RA, Pemmaraju N. Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety. Cancer 131(1), 2024. e-Pub 2024. PMID: 39616447.
Swaminathan M, Jain A, Choi SD, Pemmaraju N. Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what's the current standard of care?. Expert Rev Hematol 17(11):1-12, 2024. e-Pub 2024. PMID: 39344987.
Goulart H, Masarova L, Mesa R, Harrison C, Kiladjian JJ, Pemmaraju N. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. Br J Haematol 205(1):48-60, 2024. e-Pub 2024. PMID: 38853641.
Jen WY, Konopleva M, Pemmaraju N. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature. Cancer 130(13):2260-2271, 2024. e-Pub 2024. PMID: 38620053.
Patel AB, Masarova L, Mesa RA, Hobbs G, Pemmaraju N. Polycythemia vera: past, present and future. Leuk Lymphoma:1-13. e-Pub 2024. PMID: 38871488.
Phan L, Hammond D, Wilson NR, Groarke EM, Patnaik MM, Pemmaraju N. VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field. Leuk Lymphoma:1-13. e-Pub 2024. PMID: 38770970.
Pemmaraju N, Madanat YF, Rizzieri D, Fazal S, Rampal R, Mannis G, Wang ES, Foran J, Lane AA. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. Leuk Lymphoma 65(5):1-12, 2024. e-Pub 2024. PMID: 38391126.
Pemmaraju N, Deconinck E, Mehta P, Walker I, Herling M, Garnache-Ottou F, Gabarin N, Campbell CJV, Duell J, Moshe Y, Mughal T, Mohty M, Angelucci E. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Lymphoma Myeloma Leuk 24(4):e130-e137, 2024. e-Pub 2024. PMID: 38267355.
Pemmaraju N, Garcia JS, Perkins A, Harb JG, Souers AJ, Werner ME, Brown CM, Passamonti F. New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-XL /BCL-2 inhibition with navitoclax. Cancer 129(22):3535-3545, 2023. e-Pub 2023. PMID: 37584267.
Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, Garces S, Quesada AE, Roth M, Garcia M, McCall D, Gibson A, Ragoonanan D, Petropoulos D, Tewari P, Nunez C, Mahadeo KM, Tasian SK, Lamble AJ, Pawlowska A, Hammond D, Maiti A, Haddad FG, Senapati J, Daver N, Gangat N, Konopleva M, Meshinchi S, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 37(9):1767-1778, 2023. e-Pub 2023. PMID: 37452102.
Pemmaraju N, Kantarjian H. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Clin Adv Hematol Oncol 21(5):257-264, 2023. e-Pub 2023. PMID: 37145496.
Polverelli N, Hernández-Boluda JC, Czerw T, Barbui T, D'Adda M, Deeg HJ, Ditschkowski M, Harrison C, Kröger NM, Mesa R, Passamonti F, Palandri F, Pemmaraju N, Popat U, Rondelli D, Vannucchi AM, Verstovsek S, Robin M, Colecchia A, Grazioli L, Damiani E, Russo D, Brady J, Patch D, Blamek S, Damaj GL, Hayden P, McLornan DP, Yakoub-Agha I. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol 10(1):e59-e70, 2023. e-Pub 2023. PMID: 36493799.
Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, Pollyea D, Valent P, Brümmendorf TH, Skorski T, Patnaik M, Santini V, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RA. Perspective Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematol Oncol 40(4):491-504, 2022. e-Pub 2022. PMID: 35368098.
Adimora IJ, Wilson NR, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics. Cancer 128(16):3019-3026, 2022. e-Pub 2022. PMID: 35726525.
Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia JS, Scandura JM, Oh ST, Passamonti F, Döhner K, Mead AJ. Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer 128(13):2420-2432, 2022. e-Pub 2022. PMID: 35499819.
Bôle-Richard E, Pemmaraju N, Caël B, Daguindau E, Lane AA. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 14(9), 2022. e-Pub 2022. PMID: 35565416.
Chifotides HT, Bose P, Masarova L, Pemmaraju N, Verstovsek S. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk 22(4):210-223, 2022. e-Pub 2021. PMID: 34840087.
Wilson NR, Bover L, Konopleva M, Han L, Neelapu S, Pemmaraju N. CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma 63(1):19-30, 2022. e-Pub 2022. PMID: 34486917.
Senapati J, Daver NG, Pemmaraju N. Antibody-Drug Conjugates in Myeloid Leukemias. Cancer J 28(6):454-461, 2022. e-Pub 2022. PMID: 36383908.
Mouhayar EN, Hammond D, Lopez-Mattei J, Banchs J, Konopleva M, Pemmaraju N. Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome. JACC CardioOncol 3(5):752-755, 2021. e-Pub 2021. PMID: 34988487.
Wilson NR, Pemmaraju N. How to Treat Adult Acute Myeloid Leukemia: An Evolving Paradigm. JACC CardioOncol 3(5):747-751, 2021. e-Pub 2021. PMID: 34988486.
Wilson NR, Konopleva M, Khoury JD, Pemmaraju N. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. Clin Lymphoma Myeloma Leuk 21(11):734-740, 2021. e-Pub 2021. PMID: 34226167.
El Hussein S, Wang SA, Pemmaraju N, Khoury JD, Loghavi S. Chronic Myelomonocytic Leukemia: Hematopathology Perspective. J Immunother Precis Oncol 4(3):142-149, 2021. e-Pub 2021. PMID: 35663104.
Lee SS, Verstovsek S, Pemmaraju N. Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy. J Immunother Precis Oncol 4(3):117-128, 2021. e-Pub 2021. PMID: 35663101.
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID, Working Group CCT. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol 18(5):313-319, 2021. e-Pub 2021. PMID: 33723371.
Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv 5(8):2156-2164, 2021. e-Pub 2021. PMID: 33885751.
Pemmaraju N, Chen NC, Verstovsek S. Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 35(2):409-429, 2021. e-Pub 2021. PMID: 33641877.
Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol 144(2):1-13, 2021. e-Pub 2021. PMID: 32392559.
El Hussein S, Lyapichev KA, Crane GM, Mirza KM, Pemmaraju N, Medeiros LJ, Khoury JD, Loghavi S. Social Media for Hematopathologists: Medical Practice Reinvented-#Hemepath. Curr Hematol Malig Rep 15(5):383-390, 2020. e-Pub 2020. PMID: 33128122.
Brown SA, Daly RP, Duma N, Yang EH, Pemmaraju N, Parwani P, Choi AD, Lopez-Mattei J. Leveraging Social Media for Cardio-Oncology. Curr Treat Options Oncol 21(10):83, 2020. e-Pub 2020. PMID: 32789716.
Hammond D, Pemmaraju N. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am 34(3):565-574, 2020. e-Pub 2020. PMID: 32336420.
Economides MP, Rizzieri D, Pemmaraju N. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Curr Hematol Malig Rep 14(6):515-522, 2019. e-Pub 2019. PMID: 31853773.
Economides MP, Verstovsek S, Pemmaraju N. Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. Curr Hematol Malig Rep. e-Pub 2019. PMID: 31372878.
Kharfan-Dabaja MA, Pemmaraju N, Mohty M. Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies. Clin Hematol Int 1(1):2-9, 2019. e-Pub 2019. PMID: 34595405.
Boddu P, Carter BZ, Verstovek S, Pemmaraju N. SMAC mimetics as potential cancer therapeutics in myeloid malignancies. Br J Haematol. e-Pub 2019. PMID: 30836448.
Economides MP, Konopleva M, Pemmaraju N. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm. Ther Adv Hematol 10:2040620719874733, 2019. e-Pub 2019. PMID: 31579499.
Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community. Curr Hematol Malig Rep 13(6):581-587, 2018. e-Pub 2018. PMID: 30338458.
Goethe E, Carter BZ, Rao G, Pemmaraju N. Glioblastoma and acute myeloid leukemia: malignancies with striking similarities. J Neurooncol. e-Pub 2017. PMID: 29196926.
Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media-#MPNSM. Curr Hematol Malig Rep 12(6):598-604, 2017. e-Pub 2017. PMID: 29105027.
Pemmaraju N, Thompson MA, Qazilbash M. Disease-specific hashtags and the creation of Twitter medical communities in hematology and oncology. Semin Hematol 54(4):189-192, 2017. e-Pub 2017. PMID: 29153079.
Pemmaraju N. Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond. Curr Hematol Malig Rep. e-Pub 2017. PMID: 29064022.
Pemmaraju N, Mesa RA, Majhail NS, Thompson MA. The use and impact of Twitter at medical conferences: Best practices and Twitter etiquette. Semin Hematol 54(4):184-188, 2017. e-Pub 2017. PMID: 29153078.
Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA. Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. Curr Hematol Malig Rep. e-Pub 2017. PMID: 29064025.
Boddu P, Benton CB, Wang W, Borthakur G, Khoury JD, Pemmaraju N. Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev. e-Pub 2017. PMID: 28965757.
Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM. Curr Hematol Malig Rep. e-Pub 2016. PMID: 27492118.
Pemmaraju N, Gupta V, Thompson MA, Lane AA. Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Curr Hematol Malig Rep. e-Pub 2016. PMID: 27492117.
Benton CB, Nazha A, Pemmaraju N, Garcia-Manero G. Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol 95(2):222-42, 2015. e-Pub 2015. PMID: 25869097.
Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen related side effects. Ann Oncol 23(6):1471-4, 2012. e-Pub 2012. PMID: 22085764.

Professional Educational Materials

Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, Yilmaz M, Lyu MA, Zeng K, Sadeghi T, Cook R, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Jain N, Garcia-Manero G, Parmar S, Flowers C, Kantarjian H, Verstovsek S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes, 2024.
Pemmaraju, N. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Novel Therapeutic Approaches for a Rare Hematologic Malignancy, 2020.
Pemmaraju N, Konopleva M. Focus on Rare Blood Cancers: Novel Targeted Therapies and New Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in 2020 and Beyond.

Abstracts

Pemmaraju N, Garcia J, Potluri J, Sun Y, Harb J, Tantravahi SK, Verstovsek S, Harrison C. Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy. Cancer Research 82(12_Supplement), 2022. e-Pub 2022.
Pemmaraju N, Scott BL, Savona MR, Oh ST, Harrison C, Vannucchi AM, Palandri F, Al-Ali HK, Sobas M, McMullin MF, Gupta V, Mesa RA, Buckley S, Roman-Torres K, Verstovsek S, Yacoub AA. Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF). Journal of Clinical Oncology 40(16_Suppl), 2022. e-Pub 2022.
Pemmaraju N, Kantarjian H, Sweet K, Wang ES, Lane AA, Ali H, Stein AS, Yacoub A, Rizzieri DA, Vasu S, Gupta V, Lee S, Schiller GJ, Foran JM, Taparia MS, Rosenblat TL, Walter RB, Sieminski D, Anant M, Patnaik MM, Mughal TI, Konopleva M. Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies. Blood 138(Supp 1), 2021. e-Pub 2021.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia TM, DiNardo CD, Jabbour EJ, Pierce SA, Villarreal J, Qazilbash MH, Konopleva M, Kantarjian H. Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. Blood 138(Supp 1), 2021. e-Pub 2021.
Pemmaraju N, Bhalla KN, Daver N, Wilson NR, Fiskus WC, Ravandi F, Garcia-Manero G, Kadia TM, DiNardo CD, Jabbour EJ, Burger JA, Short NJ, Alvarado Y, Jain N, Masarova L, Verstovsek S, Issa GC, Qiao W, Khoury JD, Pierce SA, Miller D, Konopleva M, Kantarjian H, Borthakur G. Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood 138(Supp 1), 2021. e-Pub 2021.
Pemmaraju N, Konopleva M, Sweet K, Stein AS, Vasu S, Rizzieri DA, Wang ES, Kantarjian H, Brooks CL, Mughal TI, Lane AA. Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement. Blood 138(Supp 1), 2021. e-Pub 2021.
Pemmaraju N, Martinelli G, Todisco E, Lane AA, Acuña-Cruz E, Deconinck E, Wang ES, Sweet K, Rizzieri DA, Marconi G, Mazzarella L, DeAngelo DJ, Montesinos P, Gigli F, Erba HP, Konopleva M, Kantarjian H, Walter RB, Aribi A, Lebon D, Levy MY, Sloss CM, Malcolm KE, Zweidler-McKay PA, Daver N. Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 138(Supp 1), 2021. e-Pub 2021.
Pemmaraju N, Gupta V, Ali H, Yacoub A, Wang E, Lee S, Schiller G, Brooks C, Rupprecht N, Pardanani A, Tefferi A, Talpaz M, Taparia M, Mughal T, Verstovsek S, Khoury J, Patnaik M. A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. 62nd ASH Annual Meeting and Exposition, 2020. e-Pub 2020.
Pemmaraju N, Garcia J, Potluri J, Holes L, Harb J, Jung P, Hutti J, Prchal J, Verstovsek S, Harrison C. The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. 62nd ASH Annual Meeting and Exposition, 2020. e-Pub 2020.
Pemmaraju N, Gerds A, Parasuraman S, Yu J, Shah A, Xi A, Kumar S, Scherber R, Verstovsek S. Thrombosis and Risk of Mortality in Newly Diagnosed High-Risk Polycythemia Vera: An Analysis of the Medicare Claims Database in the United States. 62nd ASH Annual Meeting and Exposition, 2020. e-Pub 2020.
Pemmaraju N, Martinelli G, Todisco E, Lane A, Acuña-Cruz E, Deconinck E, Wang E, Sweet K, Rizzieri D, Mazzarella L, DeAngelo D, Montesinos P, Tarella C, Erba H, Konopleva M, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Daver P. Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). 62nd ASH Annual Meeting and Exposition, 2020. e-Pub 2020.
Pemmaraju N, Mudenda B, Wang C, JI J, Lu M, Fu T, Liang E, McClain S, Sheladia P, Verstovsek S, Yang D, Zhai Y. Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy. 62nd ASH Annual Meeting and Exposition, 2020. e-Pub 2020.
Pemmaraju N, Gerds A, Yu J, Parasuraman S, Shah A, Xi A, Kumar S, Scherber R, Verstovsek S. Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States. 62nd ASH Annual Meeting and Exposition, 2020. e-Pub 2020.
Pemmaraju N, Gupta V, Ali H, Yacoub A, Wang E, Lee S, Schiller G, Sardone M, Hoberman M, Wysowskyj H, Chen J, Brooks C, Poradosu E, McDonald P, Rupprecht N, Pardanani A, Tefferi A, Talpaz M, Taparia M, Mughal T, Verstovsek S, Khoury J, Patnaik M. Updated Results from a Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Myelofibrosis. EHA25 Virtual Congress, 2020. e-Pub 2020.
Pemmaraju N, Lane A, Sweet K, Stein A, Vasu S, Rizzieri D, Wang E, Duvic M, Spence S, Brooks C, Bergstein I, Chen J, McDonald P, Sloan J, Mughal T, Lancet J, Kantarjian H, Konopleva M. Tagraxofusp (SL-401), A CD123-Directed Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Genomic Landscape and Long-Term Results of Landmark Clinical Trial. EHA25 Virtual Congress, 2020. e-Pub 2020.
Maiti A, Dinardo C, Pemmaraju N, Kadia T, Rausch C, Naqvi K, Daver N, Borthakur G, Ohanian M, Issa G, Alvarado Y, Short N, Andreeff M, Jabbour E, Pierce S, Ravandi F, Garcia-Manero G, Welch J, Kantarjian H, Konopleva M. Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS. ASCO Virtual Scientific Program, 2020. e-Pub 2020.
Daver N, Montesinos P, DeAngelo D, Wang E, Todisco E, Tarella C, Martinelli G, Erba H, Deconinck E, Sweet K, Walter R, Levy M, Pemmaraju N, Lane A, Rizzieri D, Konopleva M, Sloss C, Wang J, Malcolm K, Zweidler-McKay P. A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies. ASCO Virtual Scientific Program, 2020. e-Pub 2020.
Pemmaraju N, Yu J, Parasuraman S, Paranagama D, Kish J, Visaria J, Singhal M, Verstovsek S, Gerds A. Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes. ASCO Virtual Scientific Program, 2020. e-Pub 2020.
Jain N, Maiti A, Ravandi F, Konopleva M, Alvarado Y, Kadia T, Short N, Borthakur G, Naqvi K, Pemmaraju N, Dinardo C, Daver N, Yilmaz M, Patel K, Linderman D, Garris R, Jabbour E, Cortes J, Kantarjian H. Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP). ASCO Virtual Scientific Program, 2020. e-Pub 2020.
Pemmaraju N, Carter B, Kantarjian H, Cortes J, Bose P, Kadia T, Garcia-Manero G, Bueso-Ramos C, DiNardo C, Bledsoe S, Daver N, Popat U, Konopleva M, Ohanian M, Pierce S, Zhou L, Estrov Z, Borthakur G, Mak P, Jain N, Jabbour E, Verstovsek S. Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis. Blood 134(Suppl 1), 2019. e-Pub 2019.
Pemmaraju N, Clementi T, Qiao W, Peterson S, Zoeller V, Schorr V, Verstovsek S. Myeloproliferative Neoplasm (MPN) Patient Online Questionnaire: Assessing Patients' Disease Knowledge in a Rare Hematologic Malignancy in the Modern Digital Information Era. Blood 134(Suppl 1), 2019. e-Pub 2019.
Pemmaraju N, Gundabolu K, Pettit K, Talpaz M, Podoltsev N, Schiller G, Eisenberg P, Youssoufian H, Duggan S, Wallner B, Verstovsek S. Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis. Blood 134(Suppl 1), 2019. e-Pub 2019.
Pemmaraju N, Borate U, Solh M, Borthakur G, DeZern A, Zhang C, Powell B, Severson P, Inokuchi K, Matusow B, Halladay J, Hsu C, Watkins P, Walling J, Tsiatis A, Mims A. Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. Blood 134(Suppl 1), 2019. e-Pub 2019.
Pemmaraju N, Gupta V, Ali H, Yacoub A, Wang E, Lee S, Schiller G, Sardone M, Wysowskyj H, Chen J, Brooks C, Poradosu E, McDonald P, Rupprecht N, Pardanani A, Tefferi A, Talpaz M, Taparia M, Verstovsek S, Khoury J, Patnaik M. Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. Blood 134(Suppl 1), 2019. e-Pub 2019.
Pemmaraju N, Kantarjian H, Khoury J, Loghavi S, O'Brien S, Cortes J, Garcia-Manero G, Jabbour E, Verstovsek S, Jain N, Duvic M, Aung P, Yin C, Konoplev S, Patel K, Pierce S, Beird H, Qazilbash M, Konopleva M. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. Blood 134(Suppl 1), 2019. e-Pub 2019.
Pemmaraju N. Results from Ongoing Ph 2 Registration Study of SL-401 in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). EHA 21st Congress, 2016. e-Pub 2016.
Sasaki K, Kantarjian HM, Ravandi F, Thomas DA, Cortes JE, Pemmaraju N, Kadia TM, Short NJ, Issa GC, Garris RS, Jeanis V, Moore H, Garcia-Manero G, Borthakur G, Wierda WG, Gachimova E, O'Brien SM, Jabbour E. Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-posititve (PH+) acute lymphoblastic leukemia (ALL). ASCO Annual Meeting 2016, 2016. e-Pub 2016.
Hu B, Kantarjian HM, Ravandi F, Borthakur G, Kadia TM, Ferrajoli A, Wierda WG, Garcia-Manero G, Daver NG, Pemmaraju N, Dellasala S, Pierce S, Jabbour E, Cortes JE. Survival outcomes of sustained MR4.5 in patients with chronic myeloid leukemia (CML) treated with various tyrosine kinase inhibitors (TKI). ASCO Annual Meeting 2016, 2016. e-Pub 2016.
Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum WG, Rizzieri D, Wang ES, Duvic M, Chen J, Shemesh S, McDonald P, Brooks C, Kantarjian HM, Konopleva M. Oral Presentation:Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing. ASCO Annual Meeting 2016, 2016. e-Pub 2016.
Cortes JE, Kantarjian HM, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Daver NG, Pemmaraju N, Jabbour E, Estrov Z, Ramachandran A, Paradela J, Pond B, Ravandi F, Vusirikala M, Patel PA, Levis MJ, Perl AE, Andreeff M, Collins R. Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. ASCO Annual Meeting 2016, 2016. e-Pub 2016.
Sasaki K, O’Brien S, Thomas DA, Khouri M, Yilmaz M, Garcia-Manero G, Ravandi F, Borthakur G, Garris R, Gachimova E, DiNardo C, Pemmaraju N, Cortes J, Kantarjian H, Jabbour E. Phase II study of hyper-CMAD with liposomal vincristine as frontline therapy for patients with acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma & Leukemia 15(Supp 2), 2015. e-Pub 2015.
Daver N, Cortes J, Zhou L, Pierce S, Pemmaraju N, Jabbour E, Borthakur G, Estrov Z, Wynn F, Van Derbur S, Garcia-Manero G, Kantarjian H, Verstovsek S. Combination Approach with Ruxolitinib and Azacytidine in Myelofibrosis. Clinical Lymphoma, Myeloma & Leukemia 15(Supp 2), 2015. e-Pub 2015.
Sasaki K, O'Brien S, Ravandi F, Thomas D, Moore HG, Cortes J, Pemmaraju N, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, Jeanis V, Borthakur G, Wierda WG, Ferrajoli A, Kantarjian H, Jabbour E. Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL). Clinical Lymphoma, Myeloma & Leukemia 15(Supp 2), 2015. e-Pub 2015.
Abraham M, Al-Rawi A, Pereg Y, Klein S, Wald H, Eizenberg O, Bulvik B, Russovsky L, Vainstein A, Aharon A, McQueen T, Pemmaraju N, Cortes J, Peled A, Borthakur G, Andreeff M. BL-8040, A NOVEL CXCR4 INHIBITOR, AFFECTS AML BLASTS SURVIVAL AND INDUCES THEIR TERMINAL DIFFERENTIATION. Clinical Lymphoma, Myeloma & Leukemia 15(Supp 2), 2015. e-Pub 2015.
Vitale C, Ciccone M, Hinojosa C, Keating MJ, Pemmaraju N, O’Brien S, Wierda WG, Thomas DA, Borthakur G, Ohanian M, Burger JA, Ferrajoli A. Front-line Treatment with Ofatumumab in Elderly Unfit Patients with CLL. Clinical Lymphoma, Myeloma & Leukemia 15(Supp 2), 2015. e-Pub 2015.
Yilmaz M, Sasaki K, Ravandi F, Cortes J, Garcia-Manero G, Kadia T, Daver N, Pemmaraju N, Borthakur G, DiNardo C, Takahashi K, O’Brien S, Estrov Z, Pike A, Brandt M, Kantarjian H. Randomized Phase II Study of Clofarabine or Fludarabine Combined with Idarubicin and Cytarabine for the Treatment of Newly Diagnosed AML. Clinical Lymphoma, Myeloma & Leukemia 15(Supp 2), 2015. e-Pub 2015.
Takahashi K, Kantarjian HM, Jain P, Jabbour E, Wierda W, Pemmaraju N, Ferrajoli A, Dellasala SE, Pierce SR, Verstovsek S, Ravandi F, O’Brien S, Cortes JE. Propensity Score Matched Comparison of Dasatinib and Nilotinib As a Frontline Therapy in Newly Diagnosed CML with Chronic Phase. Blood 124(21), 2014. e-Pub 2014.
Daver N, Kantarjian HM, Garcia-Manero G, Pemmaraju N, Kadia TM, DiNardo CD, Jain N, Borthakur G, Jabbour E, Konopleva M, Cortes J, Craig AR, Ravandi F. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood 124(21), 2014. e-Pub 2014.
Randhawa J, Kantarjian HM, Borthakur G, Thompson PA, Konopleva M, Daver N, Pemmaraju N, Jabbour E, Kadia TM, Estrov Z, Ramachandran A, Paradela J, Andreef M, Levis M, Ravandi F, Cortes JE. Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations. Blood 124(21), 2014. e-Pub 2014.
Duque AD, Cabrero M, Ravandi F, Pemmaraju N, Borthakur G, Kantarjian HM, Cortes JE, Kadia TM, Daver NG, Jabbour E, Garcia-Manero G, Sasaki K. Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience. Blood 124(21), 2014. e-Pub 2014.
Pemmaraju N, Kantarjian HM, O’Brien S, Borthakur G, Ravandi F, Verstovsek S, Daver NG, Garcia-Manero G, DiNardo CD, Skinner J, Konopleva M, Pierce S, Jabbour E, Cortes JE. Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). Blood 124(21), 2014. e-Pub 2014.
Jabbour E, Sasaki K, Daver N, Pemmaraju N, DiNardo CD, Kadia T, Miller D, Sukholutsky V, Huang X, Borthakur G, Estrov Z, Kantarjian HM, Garcia-Manero G. Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). Blood 124(21), 2014. e-Pub 2014.
Sasaki K, Jabbour E, Pemmaraju N, Daver NG, Kadia TM, DiNardo CD, Pierce SR, Borthakur G, Kantarjian HM, Garcia-Manero G. Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes). Blood 124(21), 2014. e-Pub 2014.
Jain P, Kantarjian HM, Jabbour E, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau SM, Ravandi F, O'Brien S, Cortes JE. Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 124(21), 2014. e-Pub 2014.
Randhawa JK, Jabbar KJ, Kadia T, Borthakur G, Pemmaraju N, Daver N, Kantarjian HM, Cortes JE, Hearn K, Bueso-Ramos CE, Garcia-Manero G. Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation. Blood 124(21), 2014. e-Pub 2014.
Gowin KL, Dueck AC, Verstovsek S, Daver NG, Pemmaraju N, Valdez R, Mesa RA. The Clinical Phenotype of Patients with Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis Whom Only Manifest WHO Grade 1 Fibrosis. Blood 124(21), 2014. e-Pub 2014.
Cabrero M, Garcia-Manero G, Sasaki K, Daver NG, Borthakur G, DiNardo CD, Cortes JE, Bohannan Z, Sukholutsky V, Ravandi F, Pierce S, Kadia TM, Pemmaraju N, Oran B, Champlin RE, Kantarjian HM, Jabbour E. Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. Blood 124(21), 2014. e-Pub 2014.
Cabrero M, Jabbour E, Daver N, Borthakur G, DiNardo CD, Cortes JE, Bohannan Z, Sukholutsky V, Ravandi F, Pierce S, Kadia T, Pemmaraju N, Kantarjian HM, Garcia-Manero G. Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up. Blood 124(21), 2014. e-Pub 2014.
Jabbour E, Kantarjian HM, Thomas D, Sasaki K, Ravandi F, Cortes JE, Pemmaraju N, Kadia T, Garris R, Garcia-Manero G, Borthakur G, Wierda WG, O’Brien S. Phase II Study of Combination of Hypercvad with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood 124(21), 2014. e-Pub 2014.
Pinnamaneni P, Jorgensen J, Kantarjian HM, Jabbour E, Pierce SR, Brandt M, Wang SA, Konoplev S, Konopleva M, Kornblau SM, Kadia T, DiNardo CD, Pemmaraju N, Andreeff M, Estrov Z, Garcia-Manero G, Cortes JE, Ravandi F. Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia. Blood 124(21), 2014. e-Pub 2014.
Kadia T, Borthakur G, Ferrajoli A, Daver NG, Jabbour E, Pemmaraju N, Verstovsek S, Burger JA, Wierda WG, Konopleva M, DiNardo CD, Jain N, Brandt M, Tuttle C, Wang X, Ravandi F, Garcia-Manero G, Cortes JE, Kantarjian HM. Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). Blood 124(21), 2014. e-Pub 2014.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Daver N, Verstovsek S. Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients with Myeloproliferative Neoplasm in Blastic Phase/Acute Myeloid Leukemia (MPN-AML), Accelerated Phase (MPN-AP), and DIPSS-Plus High Risk Primary Myelofibrosis (PMF). Blood 124(21), 2014. e-Pub 2014.
Garcia-Manero G, Huang X, Cabrero M, DiNardo CD, Pemmaraju N, Daver NG, Borthakur G, Wierda WG, Kadia T, Alvarado Y, Cortes J, Jain N, Ravandi F, Jabbour E, Brandt M, Sneed T, Sukholutsky V, Pierce S, Bohannan Z, Kantarjian HM. A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities. Blood 124(21), 2014. e-Pub 2014.
Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Pierce SR, Kantarjian HM, Cortes JE. Chronic Myeloid Leukemia in Chronic Phase: Survival in the Era of Tyrosine Kinase Inhibitors Is Similar to That of the General Population in All Age Groups. Blood 124(21), 2014. e-Pub 2014.
Daver N, Kantarjian HM, Garcia-Manero G, Pemmaraju N, Kadia TM, DiNardo CD, Jain N, Borthakur G, Jabbour E, Konopleva M, Cortes JE, Craig AR, Ravandi F. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood 124(21), 2014. e-Pub 2014.
Daver N, Kantarjian HM, O'Brien S, Jabbour E, Pierce SR, Lim M, Borthakur G, Pemmaraju N, Konopleva M, DiNardo CD, Ravandi F, Garcia-Manero G, Cortes JE. Frequency and Impact of Molecular Response’s with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). Blood 124(21), 2014. e-Pub 2014.
Daver N, Cortes JE, Jabbour E, Pemmaraju N, Jain N, Estrov Z, Kornblau SM, Burger JA, Kantarjian HM, Newberry KJ, Verstovsek S. Ruxolitinib and Lenalidomide As a Combination Therapy for Patients with Myelofibrosis. Blood 124(21), 2014. e-Pub 2014.
DiNardo CD, Aung FM, Martinez F, Daver N, Kadia T, Jain N, Jabbour E, Pemmaraju N, Reddy VM, Garcia-Manero G, Cortes JE, Ravandi F, Kantarjian HM, Lichtiger B, Freireich EJ. A Phase II Feasibility Study of Prophylactic White Cell Transfusions for the Prevention of Infection in AML Patients Undergoing Induction Therapy. Blood 124(21), 2014. e-Pub 2014.
Patel K, Routbort M, Noguera-Gonzalez G, Kantarjian HM, Jabbour E, Borthakur G, DiNardo C, Estrov Z, Daver N, Wierda W, Jain N, O’Brien S, Konopleva M, Cortes J, Pemmaraju N, Alvarado Y, Bueso-Ramos C, Luthra R, Singh R, Pierce S, Medeiros LJ, Bohannan Z, Huang X, Garcia-Manero G. Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes. Blood 124(21), 2014. e-Pub 2014.
DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Wei Y, Wierda WG, Bueso-Ramos CE, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood 124(21), 2014. e-Pub 2014.
Jabbour E, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Gail RJ, Daver NG, Pemmaraju N, Kadia T, DiNardo CD, Wang X, Nogueras-Gonzalez G, Borthakur G, Estrov Z, Kantarjian HM, Garcia-Manero G. Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. Blood 124(21), 2014. e-Pub 2014.
Jabbour E, Sasaki K, Daver N, Pemmaraju N, Jain N, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Faderl SH, O’Brien S, Cortes JE, Kantarjian HM, Garcia-Manero G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. Blood 124(21), 2014. e-Pub 2014.
Sasaki K, Jabbour E, Kantarjian HM, Cortes JE, Garcia-Manero G, Borthakur G, Pierce SR, Pemmaraju N, O'Brien S, Ravandi F. Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience. Blood 124(21), 2014. e-Pub 2014.
Thomas DA, O'Brien S, Rytting M, Ravandi F, Jabbour E, Ferrajoli A, Estrov Z, Garcia-Manero G, Burger JA, Wierda W, Konopleva M, Andreeff M, Kornblau SM, Verstovsek S, Borthakur G, Kadia T, Garris R, Pemmaraju N, Daver N, Jain N, Jorge Cortes J, and Kantarjian HM. Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL). Blood 124(21), 2014. e-Pub 2014.
Duque AD, Randhawa J, Kantarjian HM, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Gandhi V, Borthakur G, Cortes JE. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory / Relapsed AML. Blood 124(21), 2014. e-Pub 2014.
Borthakur G, Nagler A, Ofran Y, Rowe JM, Altman JK, Frankfurt O, Tallman, Avivi I, Peled A, Pereg Y, Foley-Comer A, Russovsky L, Aharon A, McQueen T, Pemmaraju N, Bueso-Ramos CE, Cortes J, Andreeff M. BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. Blood 124(21), 2014. e-Pub 2014.
Shetty A, Cortes JE, Ravandi F, Kadia TM, Garcia-Manero G, Pemmaraju N, Pierce S, Kantarjian HM, Borthakur G. Hyperdiploidy in AML: Outcomes of acute myelogenous leukemia (AML) patients (pts) with a hyperdiploid karyotype. Journal of Clinical Oncology 32(15), 2014. e-Pub 2014.
Andreeff M, Borthakur G, Zeng Z, Kelly MA, Wang RY, McQueen TJ, Qiu Y, Mak D, Burger JA, Daver NG, Pemmaraju N, Kadia TM, Jabbour E, Pierce S, Ravandi F, Garcia-Manero G, O'Brien SM, Cortes JE, Kantarjian HM, Konopleva M. Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients. Journal of Clinical Oncology 32(15), 2014. e-Pub 2014.
Kadia TM, Cortes JE, Borthakur G, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Ravandi F, Pemmaraju N, Daver NG, Konopleva M, Wang X, Kantarjian HM. Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML. Journal of Clinical Oncology 32(15), 2014. e-Pub 2014.
Pemmaraju N, Thomas DA, Kantarjian HM, Cortes JE, Khoury J, Manning JT, Medeiros LJ, O'Brien SM, Daver NG, Pierce S, Garcia-Manero G, Jabbour E, Jain N, Qazilbash MH, Faderl S, Frankel AE, Konopleva M. Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes. Journal of Clinical Oncology 32(15), 2014. e-Pub 2014.
Daver NG, Kantarjian H, Pierce S, Brandt M, Dinardo CD, Pemmaraju N, Vaughan K, Garcia-Manero G, Jabbour E, Borthakur G, Kadia TM, Cortes JE, Craig A, Ravandi F. Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Journal of Clinical Oncology 32(15), 2014. e-Pub 2014.
Priyanka P, Sinha A, Khoury J, Patel K, Routbort M, Singh R, Luthra R, Pemmaraju N, Takahashi K, Muzzafar T. Chronic myelomonocytic leukemia: Next-generation sequencing in 30 treatment-naive cases. Journal of Clinical Oncology 32(15), 2014. e-Pub 2014.
O'Brien SM, Jabbour E, Thomas DA, Ravandi F, Cortes JE, Pemmaraju N, Kadia TM, Garris R, Jeanis V, Garcia-Manero G, Borthakur G, Wierda WG, Kantarjian HM. Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 32(15), 2014. e-Pub 2014.
Sasaki K, Kantarjian HM, Jain P, Jabbour E, Pemmaraju N, Wierda WG, Ferrajoli A, Dellasala S, Pierce S, Verstovsek S, Ravandi F, O'Brien SM, Cortes JE. Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily. Journal of Clinical Onoclogy 32(15), 2014. e-Pub 2014.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Daver NG, Srdan Verstovsek S. Decitabine therapy for myeloproliferative neoplasm in accelerated (MPN-AP) or blastic (acute myeloid leukemia; MPN-AML) phase. Journal of Clinical Oncology 32(15), 2014. e-Pub 2014.
Daver N, Kantarjian HM, Garcia-Manero G, Pemmaraju N, Kadia T, DiNardo C, Jain N, Borthakur G, Cortes J, Adam C, Ravandi F. Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). AACR Annual Meeting 2014, 2014. e-Pub 2014.
Daver N, Kantarjian H, DeBose L, Jabbour E, Borthakur G, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo C, Ravandi F, Cortes J, Andreeff M, Konopleva M. Buparlisib, A PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I/II Trial of Patients with Advanced Leukemias. EHA Conference, Milano Italy, 2014. e-Pub 2014.
Jabbour E, Kantarjian H, Thomas DA, Ravandi F, Cortes JE, Faderl SH, Pemmaraju N, Kadia TM, Garris R, Hillary P, Garcia-Manero G, Borthakur G, Wierda WG, O'Brien S. Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting 2013 122, 2013. e-Pub 2013.
DiNardo CD, Daver NG, Jain N, Pemmaraju N, Bueso-Ramos CE, Yin C, Pierce SR, Jabbour E, Quintás-Cardama A, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural History and Clinical Outcome By Therapeutic Approach. ASH Annual Meeting 2013 122, 2013. e-Pub 2013.
Cortes JE, Borthakur G, Pemmaraju N, Daver N, Quintas-Cardama A, Ravandi F, Gachimova E, Estrov Z, Jabbour E, O'Brien S, Kantarjian H. Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP). ASH Annual Meeting 2013 122, 2013. e-Pub 2013.
Rytting ME, Thomas DA, O'Brien S, Schroeder K, Garris R, Cortes JE, Ravandi F, Pemmaraju N, Daver N, Faderl SH, Franklin ARK, Borthakur G, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting 2013 122, 2013. e-Pub 2013.
Kantarjian HM, Jabbour E, Yee K, Kropf P, O'Connell C, Stock W, Tibes R, Rizzieri D, Walsh K, Griffiths EA, Roboz GJ, Savona M, Ervin T, Podoltsev NA, Pemmaraju N, Daver N, Garcia-Manero G, Borthakur G, Wierda WG, Ravandi F, Cortes JE, Brandwein JM, Odenike O, Feldman EJ, Chung W, Naim S, Choy G, Taverna P, Hao Y, Dimitrov G, Azab M, J-P I. ASH Annual Meeting 2013. First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML) 122, 2013. e-Pub 2013.
Pemmaraju N, Shah D, Kantarjian HM, Wagner V, Orlowski RZ, Garcia-Manero G, Ravandi F, Pierce S, Takahashi K, Daver NG, Nazha A, Verstovsek S, Jabbour EJ, de Lima MJ, Champlin RE, Cortes JE, Qazilbash MH. Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). ASH Annual Meeting 2013 122, 2013. e-Pub 2013.
Daver NG, Naqvi K, Kadia TM, DiNardo CD, Ravandi F, Nazha A, Borthakur G, Pemmaraju N, Brandt M, O'Brien S, Garcia-Manero G, Pierce SR, Jabbour E, Cortes JE, Kantarjian HM. Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age. ASH Annual Meeting 2013 122, 2013. e-Pub 2013.
Frankel AE, Woo JH, Mauldin JP, Carraway HE, Frankfurt O, Forman SJ, Vasu S, Pemmaraju N, Konopleva M, Hogge DE, Garanache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Bergstein I, Rowinsky E. An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH Annual Meeting 2013 122, 2013. e-Pub 2013.
Kadia TM, Daver N, Virani F, Jabbour E, Pierce S, Pemmaraju N, Quintas-Cardama A, Borthakur G, O'Brien S, Kantarjian HM, Cortes JE. Incidence, Clinical Characteristics, and Prognostic Significance Of Chromosome 3q Abnormalities In Patients With CML Blast Phase. ASH Annual Meeting 2013 122, 2013. e-Pub 2013.
Sasaki K, Kantarjian HM, Jabbour E, Quintas-Cardama A, Pierce S, Borthakur G, Kadia TM, Pemmaraju N, Ferrajoli A, O'Brien S, Cortes JE. Clinical Safety and Efficacy Of Nilotinib Or Dasatinib In Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-Existing Liver and/Or Renal Dysfunction. ASH Annual Meeting 2013 122, 2013. e-Pub 2013.
Nazha A, Garcia-Manero G, Kantarjian HM, Ravandi F, Borthakur G, Kadia TM, Jabbour E, Pemmaraju N, Daver NG, DiNardo CD, Miller D, Faderl SH. Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy. ASH Annual Meeting 2013 122, 2013. e-Pub 2013.
Jabbour EJ, Daver NG, Dong T, Kadia TM, O'Brien S, Cortes JE, Ravandi F, Pemmaraju N, Ghanem H, Faderl S, Borthakur G, Kantarjian HM, Garcia-Manero G. Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) AFter Hypomethylating Agent (HMA). ASH Annual Meeting 2012, 2012. e-Pub 2012.
Ravandi F, Patel KP, Luthra R, Pierce SA, Borthakur G, Jabbour EJ, Kadia TM, Pemmaraju, N, Daver N, Konopleva M, Faderl S, Garcia-Manero G, Cortes JE, Kantarjian HM. Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Ghanem H, Kantarjian HM, Jabbour E, Katragadda L, Cortes JE, Pemmaraju N, Quintas-Cardama A. Biphenotypic Blast Phase (B-BP) of Chronic Myeloid Leukemia (CML): A Single Institution Experience. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Takahashi K, Pemmaraju N, Beran M, Quintas-Cardama A, Cortes JE, Ravandi F, Faderl S, Verstovsek S, Kadia TM, Borthakur G, Jabbour EJ, Daver N, Estrov Z, Pierce SA, Garcia-Manero G. Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML). ASH Annual Meeting 2012, 2012. e-Pub 2012.
Takahashi K, Jabbour EJ, Wang X, Ghanem H, Pemmaraju N, Ravandi F, Cortes JE, Faderl S, Kadia TM, Borthakur G, Wierda WG, Pierce SA, Estrov Z, Kantarjian HM, Garcia-Manero G. Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Kazmi SM, Kantarjian HM, Tran KM, Cortes JE, Ravandi F, Borthakur G, Jabbour EJ, Faderl S, Garcia-Manero G, Kadia GM, Daver N, Pierce SA, Nazha A, Quintas-Cardama A, Pemmaraju N. Cytogenetic and Molecular Charterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Hoehn D, Medeiros LJ, Pemmaraju N, Sireci A, Bhagat G, Cortes JE, Bueso-Ramos CE. Dasatinib Therapy Affects Bone Homeostatis in Patients with Chronic Myelogenous Leukemia in Chronic Phase Independently of Molecular Response. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Jain P, Kantarjian HM, Thomas DA, Ravandi F, Kadia TM, Burger JA, Borthakur G, Cortes JE, Daver N, Jabbour EJ, Koller CA, Konopleva M, Pemmaraju N, Kelly MA, Garris R, O'Brien S, Faderl S. Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL). ASH Annual Meeting 2012, 2012. e-Pub 2012.
Jain P, Kantarjian HM, Faderl S, Patel KP, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia TM, Daver NG, Nazha A, Rajyalakshmi L, Pierce SA, Cortes JE, Ravandi F. Mutant NPM1 is a Reliable marker of Minimal Residual Leukemia in Patients wtih Acute Myeloid Leukemia. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Mathisen MS, Kantarjian HM, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes JE, O'Brien S, Quintas-Cardama A, Ghanem H, Daver NG, Pierce SA, Lira C, Faderl S, Jabbour E. Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML). ASH Annual Meeting 2012, 2012. e-Pub 2012.
Daver N, Kantarjian HM, Garcia-Manero G, Estrov Z, Konopleva M, Burger JA, O'Brien S, Ferrajoli A, Verstovsek S, Kadia TM, Jabbour EJ, Faderl S, Diaz-Pines-Mateo M, Pemmaraju N, Pierce SA, Cortes JE, Borthakur G. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Quintas-Cardama A, Kantarjian HM, Ravandi F, Foudray C, Pemmaraju N, Kadia TM, Borthakur G, Daver NG, Faderl S, Jabbour E, Cortes JE, Garcia-Manero G. Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Ohanian M, Alattar ML, Estrov Z, Quintas-Cardama A, Manning JT, Ravandi F, Abruzzo LV, Cortes JE, Pemmaraju N. Myeloid Sarcoma of the Orbit and Ocular Adnexae. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Nazha A, Ravandi F, Kantarjian HM, Huang X, Choi S, Garcia-Manero G, Jabbour EJ, Borthakur G, Kadia TM, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Estrov Z, Daver NG, Pemmaraju N, Du M, Brandt M, Faderl S. Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <=60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). ASH Annual Meeting 2012, 2012. e-Pub 2012.
Ghanem H, Garcia-Manero G, Faderl S, Takahashi K, Ravandi F, Cortes JE, O'Brien SM, Daver NG, Katragadda L, Pemmaraju N, Pierce SA, Quintas-Cardama A, Kadia TM, Kantarjian HM, Jabbour EJ. Outcomes of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Romo CG, Kantarjian HM, Luthra R, Quintas-Cardama, Jabbour EJ, Borthakur G, Kadia TM, Ravandi F, Pemmaraju N, Pierce SA, O'Brien S, Cortes JE. Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 vs. b2a2 Fusion Transcripts. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Strati P, Kantarjian HM, Cortes JE, Ravandi F, Pemmaraju N, Garcia-Manero G, Kadia TM, Jabbour EJ, Nazha A, Borthakur G, Faderl S, Quintas-Cardama A, Daver NG. Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Jabbour EJ, Kantarjian HM, Cameron Y, Ravandi F, Cortes JE, Garcia-Manero G, Ghanem H, Kadia TM, Faderl, O'Brien, Mathisen MS, Brandt M, Pemmaraju N, Thomas DA, Bass J, Borthakur G. Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Daver NG, De Lima MJG, Kantarjian H, Ravandi F, Bilen MA, Pierce S, Khouri IF, Dorkhom SJ, Giralt S, Garcia-Manero G, Nazha A, Mathisen M, Pemmaraju N, Cortes JE, Faderl S, Jabbour E. Allogenic stem cell transplant (ASCT) as initial salvage for patients (pts) with acute myeloid leukemia (AML) refractory to high-dose cytarabine-based induction chemotherapy. American Society of Clinical Oncology Annual Meeting 2012, 2012. e-Pub 2012.
Bhamidipati PK, Daver NG, Kantarjian H, Pierce S, Daver R, Cortes JE, Ravandi F, Mathisen M, Pemmaraju N, Nazha A, Kadia TM, Jabbour E, Borthakur G, Faderl S, Garcia-Manero G. FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). American Society of Clinical Oncology Annual Meeting 2012, 2012. e-Pub 2012.
Kadia TM, Jabbour E, Pemmaraju N, Faderl S, Borthakur G, Thomas DA, Daver NG, Ravandi F, Kantarjian H. Phase II study of omacetaxine (OM) and low-dose AraC (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). American Society of Clinical Oncology Annual Meeting 2012, 2012. e-Pub 2012.
Pemmaraju N, Thomas DA, Kantarjian H, O'Brien SM, Daver NG, Nazha A, Pierce S, Garcia-Manero G, Cortes JE, Faderl S. Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN). American Society of Clinical Oncology Annual Meeting, 2012. e-Pub 2012.
Hoehn D, Pemmaraju N, Cortes JE, Wang X, Kanagal-Shamanna R, Dellasala SE, Nazha A, Kantarjian HM, Medeiros LJ, Bueso-Ramos CE. Dasatinib Affects Bone Homeostasis, Independent of Molecular Response, in Patients with Chronic Myelogenous Leukemia (CML). Canadian Academy of Pathology's 101st Annual Meeting, 2012. e-Pub 2012.
Pemmaraju N, Thomas D, Kantarjian HM, Cortes JE, Manning JT, Medeiros LJ, O'Brien S, Daver NG, Nazha A, Pierce SA, Garcia-Manero G, Jabbour EJ, Faderl S. Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Pemmaraju N, Kantarjian HM, Cortes JE, Quintas-Cardama A, Pierce SA, Verstovsek S. Incidence and Outcomes of Myeloproliferative Neoplasms (MPN) in Adolescents and Young Adults (AYAs). ASH Annual Meeting 2012, 2012. e-Pub 2012.
Pemmaraju N, Kantarjian HM, O'Brien S, Kadia TM, Cortes JE, Borthakur G, Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Quintas-Cardama A, Jabbour EJ, Koller CA, Dellasala SE, Pierce SA, Burton EM, Verstovsek S. Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia. ASH Annual Meeting 2012, 2012. e-Pub 2012.
Pemmaraju N, Kantarjian HM, Tran KM, Kazmi SM, Kadia TM, Borthakur G, Verstovsek S, O'Brien S, Garcia-Manero G, Estrov Z, Faderl S, Ravandi F, Pierce SA, Cortes JE, Quintas-Cardama A. Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML). ASH Annual Meeting 2012, 2012. e-Pub 2012.
Kadia T, Garcia-Manero G, Kantarjian H, Pemmaraju N, Stein K, Teng A, Cortes J. Retrospective analysis of effects of transfusion status on response to decitabine and survival in patients with myelodysplastic syndromes. Journal of Clinical Oncology 29(15):Abstr 6608, 2011. e-Pub 2011.
Pemmaraju N, Ravandi F, Rondon G, Giralt S, Chen J, Pierce S, Champlin R, DeLima M, Qazilbash M. Analysis of outcomes in patients (pts) with relapsed/refractory acute promyelocytic leukemia (APL) treated with and without high-dose chemotherapy and hematopoietic stem cell transplantation (HCT). Journal of Clinical Oncology 29(15):Abstr 6608, 2011. e-Pub 2011.
Takahashi K, Kantarjian H, Pemmaraju N, Borthakur G, Faderl S, Garcia-Manero G, Andreeff M, Pierce S, Ravandi F, Cortes J. FLT3 inhibitors are promising salvage therapy for relapsed or refractory acute myeloid leukemia in patients with FLT3-ITD mutations. American Society of Hematology Annual Meeting 2011, 2011. e-Pub 2011.
Pemmaraju N, Kantarjian H, Tanaka MF, O'Brien S, Jabbour E, Quintas-Cardama A, Borthakur G, Ravandi F, Verstovsek S, Burton E, Walker B, Cortes J. Memory impairment in chronic phase chronic myeloid leukemia patients treated with dasatinib tyrosine kinase inhibitor therapy. American Society of Hematology Annual Meeting 2011, 2011. e-Pub 2011.
Gushiken F, Vo YD, Xiao L, Kadia T, Cortes JE, Pemmaraju N, Pierce S, Kantarjian H, Borthakur G. Coagulation profile as prognostic indicator in acute myeloid leukemia. American Society of Hematology Annual Meeting 2011, 2011. e-Pub 2011.
Pemmaraju N, Kantarjian H, Luthra R, O'Brien S, Jabbour E, Quintas-Cardama A, Borthakur G, Ravandi F, Verstovsek S, Burton E, Walker B, Cortes J. Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia in chronic phase. American Society of Hematology Annual Meeting 2011, 2011. e-Pub 2011.
Pemmaraju N, Kantarjian H, O'Brien S, Verstovsek S, Jabbour E, Quintas-Cardama A, Garcia-Manero G, Borthakur G, Ravandi F, Shan J, Cortes J. Seven-year follow-up data on sequential prospective trials of imatinib 400mg vs 800mg daily schedule for front-line treatment of chronic myeloid leukemia (CML). Blood 116(21):Abstr 3438, 2010. e-Pub 2010.
Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults (AYA) with chronic myeloid leukemia (CML) treated with upfront tyrosine kinase inhibitors (TKI). Blood 116(21):Abstr 1234, 2010. e-Pub 2010.
Pemmaraju N, Kantarjian H, Garcia-Manero G, Faderl S, Ferrajoli A, Borthakur G, Kadia T, Cortes J. Phase I study results of gimatecan in the treatment of myelodysplastic syndrome (MDS). Blood 116(21):Abstr 1883, 2010. e-Pub 2010.
Pemmaraju N, Kantarjian H, Faderl S, Garcia-Manero G, Kadia T, Borthakur G, Cortes J, Ravandi Kashani F. Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS). Journal of Clinical Oncology 28(15):Abstr 6605, 2010. e-Pub 2010.
Pemmaraju N, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Parikh S, Konopleva M, Kornblau S, Andreeff M, O'Brien S, Cortes J. FLT3 inhibitor therapy for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): impact on survival according to FLT3 status. Blood 114:Abstr 1026, 2009. e-Pub 2009.
Pemmaraju N, Kantarjian H, Ravandi F, O'Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J. Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience. Journal of Clinical Oncology 27(15):Abstr 7051, 2009. e-Pub 2009.
Pemmaraju N, Kantarjian H, Ravandi F, O’Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J. Acute myeloid leukemia in adolescents and young adults (AYA): The MD Anderson Cancer Center (MDACC) experience. Blood 112:Abstr 3982, 2008. e-Pub 2008.
Stein B, Williams D, Rogers O, Isaacs M, Pemmaraju N, Moliterno A. Gender is a phenotypic modifier in the JAK2 V617F-positive MPD. Blood 112:Abstr 1761, 2008. e-Pub 2008.

Book Chapters

Kale, BJ, Wilson, NR, Pemmaraju, N. Chimeric Antigen Receptor Therapy in Acute Myeloid Leukemia, 205-216, 2023.
Deconinck E, Lane A, Pemmaraju N, Garnache Ottou F. Management, Unmet needs and future directions. In: Fast Facts: Blastic Plasmacytoid Dendritic Cell Neoplasm. S. Karger Publishers Ltd, 36-49, 2021.
Kainthle R, Kadia T, Pemmaraju N. Leukemia. In: Handbook of Targeted Therapy. Springer, 2015.
Pemmaraju N, Cortes J. FLT3-ITD. Clinical (Sorafenib/AC220). In: Targeted Therapy of Acute Myeloid Leukemia, 2015.
Pemmaraju N, Garcia-Manero G, Ravandi F. Methylation in AML-Clinical Applications. In: Targeted Therapy of Acute Myeloid Leukemia, 2015.
Pemmaraju N, Parikh S, Jabbour E, Kantarjian H, Cortes J. Chronic Myeloid Leukemia. In: MD Anderson Manual of Oncology. 2nd, 2011.
Pemmaraju, N. Blastic plasmacytoid dendritic cell neoplasm. In: 5th Edition of the WHO Classification of Tumours (“WHO Blue Books”). 5th. International Agency for Research on Cancer (IARC).

Letters to the Editor

Senapati J, Garcia-Manero G, DiNardo CD, Deshmukh I, Borthakur G, Kadia TM, Jabbour E, Short NJ, Abbas HA, Pemmaraju N, Jain N, Haddad FG, Issa GC, Maiti A, Shpall E, Popat U, Loghavi S, Tang G, Yilmaz M, Alvarado Y, Montalban-Bravo G, Ravandi F, Kantarjian HM, Daver NG. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone Marrow Transplant 60: 910-913, 2025.
Swaminathan M, DiNardo CD, Maiti A, Pemmaraju N, Ohanian M, Daver NG, Garcia-Manero G, Issa GC, Borthakur G, Ravandi F, Montalban-Bravo G, Kadia TM, Alvarado Y, Jabbour EJ, Short NJ, Wierda WG, Jain N, Kornblau SM, Masarova L, Pierce SA, Qiao W, Ning J, Kantarjian H, Konopleva MY. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial. Blood Cancer J 15: 52, 2025.
Kawedia JD, Rausch CR, Liu X, Qiao W, Dinardo CD, Daver N, Borthakur G, Pemmaraju N, Reville P, Kontoyiannis DP, Short N, Konopleva M, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals. Am J Hematol 100: 740-743, 2025.
Mustafayev K, Yepez Guevara E, DiNardo CD, Jabbour E, Ghayas IC, Ratan R, Pemmaraju N, Torres HA. Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study. Leuk Res 147: 107597, 2024.
Jen WY, Jabbour E, Short NJ, Issa GC, Haddad FG, Jain N, Pemmaraju N, Daver NG, Masarova L, Borthakur G, Chien K, Garris R, Kantarjian HM. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. Am J Hematol 99: 2229-2232, 2024.

Less

CV information above last modified October 01, 2025

Naveen Pemmaraju, M.D.

About Dr. Naveen Pemmaraju

In the News

Leukemia specialists: How advances in measurable residual disease (MRD) are improving cancer care

ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis

Understanding the types of leukemia

Reflections on caring for cancer patients during the COVID-19 pandemic

New blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment improves outlook for many patients

Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies

Acute myeloid leukemia: What to know

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Professional Educational Materials

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Department of Leukemia

Division of Cancer Medicine

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop MD Anderson